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LIST OF ABBREVIATIONS
IN ALPHABETICAL ORDER
S-ACE: Serum angiotensin-converting enzyme level
S-Afos: Serum alkaline phosphatase level
BHL: Bilateral hilar lymphadenopathy
S-Ca: Serum calcium level
U-Ca: Urinary calcium level
DLco: Diffusing capacity for carbon monoxide
EN: Erythema nodosum
ESR: Erythrocyte sedimentation rate
FEV1: Forced expiratory volume in one second
FVC: Forced vital capacity
B-Hb: Blood haemoglobin level
HLA: Human leukocyte antigen
HLA-Cw*: Human leukocyte antigen-Cw (DNA determined by PCR)
B-leuk: Blood leukocyte count
S-LZM: Serum lysozyme level
PCR: Polymerase chain reaction
Chest radiographs:
Stage I: Bilateral hilar lymphadenopathy
Stage II: Parenchymal shadows and bilateral hilar lymphadenopathy
in chest
Stage III: Parenchymal shadows alone
Stage IV: Fibrotic changes
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1. INTRODUCTION
Sarcoidosis is a multi-organ granulomatous disease the cause of which is
unknown, most often affecting the lungs, eyes, skin and peripheral lymph
nodes. Sarcoidosis is most prevalent in young and middle-aged individuals
with a slight female predominance (1). The mode of presentation, clinical
picture and course of sarcoidosis vary considerably (2). Sarcoidosis is most
often a benign disease from which recovering is slow. Fifty percent of
patients with initial stage-I changes in their chest radiographs (bilateral
hilar lymphadenopathy) have normal radiographs within two years. Patients
with stage-II to stage-III changes (parenchymal infiltrates with or without
bilateral hilar lymphadenopathy) need longer times before radiographs
become normal. Corticosteroids have been found beneficial to control
symptoms and improve the rate of clearance of radiographic changes.
Whether the long-term prognosis in sarcoidosis is affected by current
treatment is however a matter of debate (3, 4). International guidelines
relating to management and treatment strategies with which all physicians
might be satisfied have been lacking. However, a very new statement has
just been made by three organisations [American Thoracic Society (ATS),
European Respiratory Society  (ERS) and  World  organisation of Sarcoidosis
and  Other Granulomatous Diseases (WASOG)] to quide physicians in
makeing diagnosis and in treating patients with sarcoidosis (5).
Epidemiological studies may aid understanding of causes of sarcoidosis.
Great variations have been observed between ethnic groups in relation to
susceptibility to development of sarcoidosis, and in relation to the clinical
picture of and outcome in the disease (1, 4, 6). Sarcoidosis is commonest
in northern Europe and the USA. There is an impression that it is rare in
Chinese, inhabitants of south-east Asia, black Africans in tropical zones,
and north American Indians (7a).
It has been reported, that there are differences in prevalences, clinical
pictures and outcomes relating to sarcoidosis between Finland and
Hokkaido, Japan (8, 9, 10, 11, 12) despite similarities between these areas.
10
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Finland is a northern European country, Hokkaido a northerly island of
Japan. Both areas have four-season climates, with cold winters and cool
summers (13). Population numbers are similar, at about 5 million.
Frequencies of occurrence of tuberculosis are similar. In 1983, the incidence
of tuberculosis in Finland was 39.2 per 100,000 inhabitants, in Hokkaido
34.5 per 100,000. Having regard to the reported differences and known
similarities, it was felt, that comparison of sarcoidosis in the two areas
would be of interest.
11
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2. REVIEW OF LITERATURE
2.1. Incidence and prevalence of sarcoidosis
2.1.1. Worldwide incidence and prevalence of sarcoidosis
Sarcoidosis occurs throughout the world but is most prevalent in northern
Europe and the USA (1,14). Sarcoidosis very often affects the intrathoracic
organs. More than 90% of sarcoidosis patients exhibit intrathoracic lesions
at some stage of the disease (7b, 14). Health-screening surveys intended to
detect tuberculosis, are one of the most useful sources of data for
epidemiological studies on sarcoidosis. Reported prevalences have varied
largely depending on how frequently screening surveys have been carried
out but also because of differences in diagnostic criteria in various countries.
Hospital records also provide useful information about numbers of patients
having the diagnosis of sarcoidosis.
In most studies a slightly higher overall incidence of sarcoidosis has
been found in women than in men. Highest age-adjusted incidences in
both sexes have been found in the age group 20-40 years (1, 3, 6). A slight
peak in incidence has also been seen in middle-aged women (3, 6).
However, in India male predominance, with the highest incidence in patients
more than 40 years of age, has been found (15, 16).
In almost all studies on sarcoidosis only a few cases below age 15 years
have been reported. Siltzbach and Greenberg surveyed 1,050 sarcoidosis
cases and found 18 (1.7%) below age 15 years, of which only five were
below age nine years (17). In the Nordic countries only 4% of sarcoidosis
patients have been 19 or fewer years of age (18). Differences in incidences
and prevalences of sarcoidosis between different races and areas have been
reported. Afro-Americans have been found to be most susceptible to the
disease (1, 19). Some studies on the incidence and prevalence of sarcoidosis
throughout the world are listed in Table I.
12
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Table I:
Examples of epidemiological studies on sarcoidosis.
Author(s) Ref. Publication Population surveyed, Epidemiological
year number of features
sarcoidosis cases
James 14 1992 Worldwide, 3676 >50% of patients were
<40 years of age
Hillerdal 3 1984 Swedish, 505 A peak in prevalence in
et al. relation to women in
middleage and older
Hosoda 6 1988 World wide, 4487 As above
Gupta et al. 15 1985 Indian, 90 Male predominance,
patients more than
40 years of age
Gupta & 16 1990 Indian, 125 As above
Gupta
Siltzbach & 17 1968 American, 1050 Sarcoidosis rare in
Greenberg those younger than
19 years of age
Milman & 18 1990 Scandinavians, 7683 As above
Selroos
James 14 1992 Worldwide, 3676 Highest susceptibility
in Afro-Americans
Cooch 19 1961 U.S. Army personnel, As above
462 sarcoidosis cases
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2.1.2. Incidence and prevalence of sarcoidosis in Finland
In 1960 Riska and Selroos performed  the first epidemiological study in
Finland of hospitalized sarcoidosis patients. They analysed data from the
Statistical Department of the Finnish Medical Board. Forty-eight verified
and 23 suspected sarcoidosis cases were found, giving an estimated
prevalence of 1.6 per 100,000 (20). In 1960-1961 Pätiälä et al. surveyed
mass-radiographs and esimated the prevalence of sarcoidosis to be 4.6 per
100,000. On surveying mass-radiographs from southern Finland in 1960-
1962 they found a prevalence of 5.1 per 100,000 (21). In a six-year study
in southern Finland from 1959-1965 Selroos examined incidences,
prevalences and the nature of sarcoidosis. He reported an annual incidence
ranging from two to 16 per 100,000. The mean prevalence of sarcoidosis
during the period was 8.0 per 100,000 (22). The findings reported were
similar to reported for Denmark and Sweden (18). Selroos then studied
sarcoidosis in 12 areas in Finland in which the epidemiological situations
with regard to tuberculosis differed. He reported the average annual
incidence to be 5.3 and the prevalence to be 7.5 per 100,000. No correlation
with prevalence of tuberculosis was demonstrated (8). Elo conducted an
epidemiological study of sarcoidosis in south-western Finland from 1965-
1977. It involved 356 sarcoidosis cases detected by mass-radiographic
surveys and clinical examinations, of which 286 were biopsy-proven.
Reported incidences and prevalences were the highest ever seen in Finland:
an average annual incidence of 17.6 and prevalence of 102 per 100,000 (9).
The most recent epidemiological study in Finland was related to 1971-1980.
It was based on 354, of which 95% were histologically verified cases in
northern Finland giving an average annual incidence of 14.2 in men,
15.3 per 100,000 in women (10).
Finnish sarcoidosis incidences by age and sex have been found to exhibit
a peak in the age group 30-39 years, especially in women, with another
peak in the age group 50-59 years (20, 22). However, in a later study the
highest incidence in women was in the age group 40-49 years (8). The
incidence in men has consistently been highest in age group 20-39
years (8, 9, 10). The above-mentioned epidemiological Finnish studies are
listed in Table II.
14
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TableII:
Epidemiological studies on sarcoidosis in Finland up to 1984
Author(s) Ref. Year(s) Study Type of Prevalence Incidence
population study per per
and area 100,000 100,000
Riska & 20 1960 Hospital patients Hospital 1.6
Selroos in Finland survey
Riska & 20 1960- Southern and south- Mass X-ray 5.1
Selroos 1962 western Finland;
210.000 inhabitants
Pätiälä 21 1960- All Finland; Mass X-ray 4.6
et al. 1961 1,450,000 X-rays;
4,477,000
inhabitants
Selroos 22 1959- Southern and Mass X-ray 8.1 7.6
1965 south-western (2.5-18.3) (1.9-16.1)
Finland;
357,180 inhabitants
15 years of age
or over
Selroos 8 1962- 12 tuberculosis Mass X-ray 7.5
1967 districts with (confirmed
different cases)
incidences and
prevalences of
tuberculosis;
1,530,000 X-rays
Elo 9 1965- South-western Hospital 102 17.6
1977 Finland; series (25-152) (14.4-21.2)
999,900 X-rays; 1965-1977
378,300 and mass
inhabitants X-ray
1974-1977
Poukkula 10 1970- Northern Two hospital 15
et al. 1981 Ostrobothnia; series; 95%
300,000 with
inhabitants histological
15 years of age confirmation
or over
15
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2.1.3. Incidence and prevalence of sarcoidosis in Hokkaido
In Japan nationwide sarcoidosis surveys have been conducted every third to
sixth year since 1959 (1, 23, 24). Sources for surveys have been hospitals
with 150-200 or more beds. Findings have been based on mass-radiographic
surveys and hospital records. Reported incidences from the outset to 1984
gradually increased beginning with an overall incidence of 0.1 but rising
to 1.2 in men and 1.4 in women per 100,000 in 1984. Similar increases in
prevalences have been seen. In the 1963 and 1968 surveys overall
prevalences were 1.2 and 3.9 per 100,000, respectively. In the 1972 and
1984 surveys the prevalences in men were 3.0 and 3.8 per 100,000, in
women 3.3 and 5.6 per 100,000, respectively.
In Japan, sarcoidosis has been commoner in northern and eastern regions
than in southern and western parts. In 1974 Hosoda presented figures from
three sources: Ministry of Health and Welfare surveys from 1960-1961, 1964
and 1970, The Ten-Year Study (1961-1970) of the Japanese National
Railways Sarcoidosis Study Team, and The Joint Study Teams’ annual mass-
radiographic surveys of school cildren. Highest incidence rates were found
in Hokkaido (4.8 per 100,000) and Tohoku (3.1 per 100,000). In other
parts of Japan the incidenceses ranged from 0.5 to 1.6 per 100,000. (25).
In 1974 Hiraga et al. reported separately on the Ten-Year Study (1961-1970),
which was based on mass-radiographic surveys and clinical examinations
of Japanese railway workers. Sixty-six sarcoidosis cases were found,
of which only five were women. Highest incidences were in Hokkaido
(10.5 per 100,000), Tohoku (6.2 per 100,000) and Kanto (6.6 per 100,000)
in personnel of 29 or fewer years of age. In other regions of Japan
incidences ranged fom 1.2 to 5.6 per 100,000. In personnel of 30 or
more years of age incidence in Japan varied from 1.2 to zero. Incidence
was 1.0 per 100,000 in Hokkaido (26). In 1977 Hiraga reported on an
outbreak of sarcoidosis in Furano, Hokkaido. The prevalence of sarcoidosis
was 140 per 100,000 inhabitants (27). On the basis of six nationwide
Japanese sarcoidosis surveys, Yanagawa et al. reported on regional
differences in prevalences. Northern Japan, Hokkaido, and Akita and
Miyagi had prevalences of more than twice the average prevalence for
Japan (28). In the first nationwide survey a male predominance (1.2:1) was
found, with peak incidence in the age group 20-29 years (29). In subsequent
nationwide surveys age-adjusted incidences were highest around age 20
for both sexes. Incidences in women peaked around ages 40 and 50 years,
but there were only slight peaks in men of the same ages (28). Japanese
epidemiological studies on sarcoidosis are listed in Table III.
16
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TableIII:
Epidemiological sarcoidosis studies in Japan up to 1984 with special
reference to Hokkaido. Non-age-adjusted incidences and prevalences
shown.
Nation- Ref. Year(s) Study Type of Prevalence Incidence New cases
wide population study per per in
study no. and area 100,000 100,000 Hokkiado
I 24 1959 Large Mass  X-ray 0.1 13
hospitals and hospital
examinations
II 24 1961 Hospitals As above
with 159 or
more beds,
TB sanatoria
and health
centres
III 24 1962- As above As above 0.4 63
1964
IV 24 1965- As above As above 0.4 117
1969
V 23, 1972 As above As above 1.4(0.2-5.3) 0.9
24 3.0a, 3.3c 1.2b, 1.4d
VI 24 1973- As above As above 0.9
1977
VII 12 1984 As above As above 3.8a, 5.6c 1.2b, 1.4d 288
a= estimated prevalence for men in Japan overall, c= for women;
b= estimated incidence for men in  Japan overall, d= for women.
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2.2. Clinical picture of sarcoidosis
2.2.1. Worldwide clinical picture of sarcoidosis
Since Hutchinson (1869) described  the skin disease, later called sarcoidosis,
a vast number of papers on symptoms and findings have been published.
In the 1980s more than 600 papers were published on pulmonary
sarcoidosis alone. Almost every organ in the human body has shown to be
a possible target. According to a worldwide review of 3676 sarcoidosis
patients the commonest target organ was the lung. On average, 51% of
patients had stage-I lesion, 41% had stage-II or stage-III lesions. Of
extrathoracic findings, peripheral lymphadenopathy was present in 22%
of cases [range 0.3 (Naples) to 37% (New York)]. Erythema nodosum (EN)
was found in 17% of cases [range 4% (Tokyo) to 33% (Edinburgh)]. The
third commonest extrathoracic finding was ocular sarcoidosis [15%, range
0% (Naples) to 33% (Tokyo)]. All other extrathoracic findings occurred in
fewer than 10% of cases (14).
The clinical picture in sarcoidosis varies from absence of symptoms to
several severe symptoms (2, 6, 7c). In numerous reports as many as half of
the patients have initially been asymptomatic (3, 18). The most commonly
reported symptoms have been respiratory (30). More than 90% of
sarcoidosis patients exhibited lung changes at some time point (7b, 7d,
30).
Racial differences have been found to influence the clinical picture in
sarcoidosis considerably. In a study relating to the Nordic countries, covering
30 years, a typical picture on presentation was acute sarcoidosis with BHL
and EN, often combined with arthralgy (18). Similar findings have been
reported from London (31). In Afro-Americans sarcoidosis has been found
to be more serious often involving extensive pulmonary fibrosis, and
extrathoracic lesions affecting the skin, heart, brain and kidney (31, 32,
33). Many patients with sarcoidosis (over 50% in some cases) are tuberculin-
skin-test negative (34, 35, 36).
2.2.2. Clinical picture of sarcoidosis in Finland
Almost 50% of Finnish sarcoidosis patients were asymptomatic on
presentatíon and were identified via mass-radiographic surveys (8, 9). In
symptomatic patients cough is the commonest symptom, in 25-29% of
cases (8, 10). Acute sarcoidosis with EN is the typical clinical picture in all
18
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Nordic countries. In Finnish series the percentage of EN has ranged from
18 to 39 (8, 9, 10).
Almost all Finnish sarcoidosis patients exhibit pulmonary findings at
some time. In 1964 Riska and Selroos reported pulmonary lesions in 69 of
71 verified sarcoidosis patients (15). In other series all of the 140 (8) and
356 patients (9) exhibited chest radiographic changes. Poukkula et al.
reported that 15 of 354 sarcoidosis patients had a normal chest radiographs
(10).
Radiographic stage-I, stage-II and stage-III findings have been reported
in 55, 39 and 6% of cases (8), 25, 72 and 3% of cases (9) and 62, 34 and
3% of cases (10), respectively. Stage-I changes have therefore been the
commonest chest-radiography finding in two of the three largest Finnish
epidemiological studies on sarcoidosis.
The commonest extrathoracic findings have been changes in peripheral
lymph nodes, in 3-29% of cases (8, 9, 10), eyes, in 4-28% of cases (8, 9,
10, 37), and skin, in 2-6% of cases (8, 9, 10).
More than half of Finnish sarcoidosis patients have had positive
tuberculin-skin-test results. Selroos reported positive skin-test results in
52% of patients, to 1 or 10 TU (tuberculin units) PPD (purified protein
derivative) and Elo in 59% of patients to 1, 10 or 100 TU PPD. Test results
were more often positive in patients with BHL than in patients with
parenchymal lesions (8, 9). A lower incidence of tuberculin-skin-test
positivity was reported by Poukkula et al. Of 332 tuberculin-tested patients
only 25% reacted positively to 1 TU PPD. The test was not continued using
higher concentrations. Poukkula et al. showed, however, that test  results
were positive as often in patients who had undergone BCG vaccinations as
in those who had not (10).
2.2.3. Clinical picture of sarcoidosis in Hokkaido
Data from six nationwide Japanese sarcoidosis surveys reveals that half of
the patients were initially symptom-free. Asymptomatic patients were
commoner in younger than in older age groups. Photophobia was the
commonest symptom, in more than 20% of cases. Cough was the second
commonest symptom (4%). BHL was twice as common as parenchymal
shadows (28).
In the two nationwide surveys of sarcoidosis in 1972 and 1984, patients
were divided in to two groups, annually patients in prevalence and incidence
studies. In both surveys and both groups BHL was present in about 90% of
19
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the patients. In prevalence patients the percentage of cases with parenchymal
lesions increased from 38 to 43, with eye lesions from 31 to 44% from
1972 to 1986 (12). Sarcoidosis patients in Furano, Hokkaido, exhibited
BHL in 95% of cases. Fifty-three per cent exhibited some type of
extrathoracic lesion. One third had eye lesions (27).
In the first Japanese nationwide survey, of 94 patients, it was found that
in addition to pulmonary changes patients had also exhibited extrathoracic
manifestations such as lesions of peripheral lymph nodes, eyes and skin.
However, no EN was seen. Sixty-eight of 84 patients (81%) were tuberculin-
negative (29). On continuing the study one case of EN was found (38).
Among extrathoracic findings, eye lesions were the commonest but skin
lesions were also often seen. Hosoda (1974) reported eye lesions in 36%
of men and 46% of women, and skin lesions in 19% of men and 9% of
women. Changes in chest radiographs were commonest in young patients.
Eye and skin lesions were commonest in older age groups (28).
2.3. Outcome in sarcoidosis
2.3.1. Worldwide outcome in sarcoidosis
Many studies have been performed with the aim of identifying prognostic
factors in sarcoidosis. Several factors associated with poor outcome have
been reported, e.g. silent insidious onset (40) initial respiratory symptoms
(41), pulmonary fibrosis, large skin infiltrations, lupus pernio, bone cysts,
upper respiratory-tract changes, chronic uveitis, keratoconjunctivitis sicca,
advanced age, black race (7e, 42, 43, 44), persistent lymphocytosis and
high initial IgG content of BAL fluid (45). The only factors associated with
good outcome have been acute onset of sarcoidosis together with BHL
and EN, and preserved-tuberculin-skin-test positivity (34, 40, 42, 46).
Eighty to 94% of patients initially exhibiting EN have been shown to
experience complete remission (18, 42, 47). Highest remission rates have
been reported for patient groups with EN with BHL. In 1990 Milman and
Selroos reviewed Nordic sarcoidosis studies and showed on basis of
combined data from Danish, Finnish and Swedish studies that 88% of patients
with acute onset of sarcoidosis together with EN and BHL experienced
complete remission of disease within two years (40).
Over-all clear-up rates for the sarcoidosis population overall have varied.
In a survey of 3676 sarcoidosis patients worldwide (14) 65% had normal
20
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chest radiographs during follow-up, in the Nordic survey (40) 74% of cases
had normal chest radiographs during follow-up. On grouping patients
according to initial chest-radiographyc findings, patients with stage-I and
stage-II changes were found to have more favourable outcomes than those
with stage-III changes. In a 10-year Swedish follow-up study, after a
5-year observation period 82% of patients with initial stage-I changes
presented a normal picture, and 68% of stage-II patients but only 33% of
stage-III patients (3). For combined data for Nordic countries the
corresponding clear-up percentages were 82% (stage-I), 66% (stage-II) and
30% (stage-III) (40). In contrary, Afro-Americans and Indians had less
favourable outcomes even when BHL was found on presentation (16, 32,
48, 49).
Age has been found to be of importance in relation to outcome in
sarcoidosis. On presentation, about one third of sarcoidosis patients were
more than 40 years of age. Such sarcoidosis patients had, even on
presentation, more symptoms and more severe extrathoracic changes than
younger patients. Treatment with glucocorticosteroids was more often
necessary and clinical course worse than in younger patients (2, 3, 50).
In a study of 194 sarcoidosis patients (including nine Afro-Americans)
in the Mayo Clinic, the 10-year survival rate for sarcoidosis patients was
80%. The survival rate for the basic population was 91% (51). In a study of
184 Afro-American sarcoidosis patients the survival rate was 85%. In the
basic population it was 95% (52). In the Nordic countries patients with
initial stage-I changes had approximately the same mortality rate as the
basic population but patients with stage-II to stage-IV changes had a
mortality rate of 5.9%, three times that expected (40). In a Danish survey,
extrapulmonary lesions did not increase the mortality rate in sarcoidosis
patients but initial respiratory symptoms and a decreased FEV1 did (53).
Epidemiological studies of the effects of initial chest-radiography findings
on outcome in sarcoidosis and relating to some other topics are listed in
Table IV.
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Table IV:
Epidemiological studies on sarcoidosis worldwide and some aspects
relating to outcome.
Author(s) Ref. Publication year Population surveyed Outcome aspects
James 14 1976 3676 persons Overall normalization rate
et al. world-wide for chest X-rays during
5-year follow-up 65%
Milman & 40 1990 5310 Scandinavians Normalization rate 74%
Selroos
Hillerdal 3 1984 505 Swedes Normalization rate on chest
et al. radiographs during
5-year follow-up:
Stage I: 82%/ II: 65%/ III: 33%
Milman & 40 1990 5310 Scandinavians Normalization rates:
Selroos Stage I: 82%/ II: 66%/ III: 30%
Sones & 48 1961 211 Americans Afro-Americans and Indians
Israel had less favourable outcomes,
even with initial
stage-I sarcoidosis
Israel & 32 1980 322 Americans As above
Washburne
Gupta 49 1988 State-of-the-art As above
lecture
Gupta & 16 1990 125 Indians As above
Gupta
Mayock 2 1963 145 Americans Patients 40 or more years
et al. of age had worse clinical
courses outcomes than
younger patients
Hillerdal 3 1984 505 Swedes As above
et al.
Margolis & 50 1983 12 Americans As above
Israel
Milman & 40 1990 5310 Scandinavians Stage-II and stage-III patients
Selroos had high mortality rates
Carr & 51 1954 149 Americans Survival rates were lower in
Gage sarcoidosis population than
in the basic population
(80% versus 91%)
Sones & 52 1960 184 Afro-Americans Survival rates were lower in
Israel sarcoidosis population than
in the basic population
(85% versus 95%)
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2.3.2. Outcome in sarcoidosis in Finland
In Finland, outcome in sarcoidosis has been investigated in several studies
(8, 9, 10, 54, 55).
Hannuksela et al. observed 135 sarcoidosis patients with acute untreated
disease. They found outcome to be very good  in patients with initial BHL
and EN. The resolution rate during 2 years of follow-up was 93%. In
patients with EN and stage-II changes it was 63%. In patients with stage-I to
stage-II changes but no EN it was 73% (54).
In an earlier study Hannuksela et al. had found an association between
positive tuberculin-skin-test results, acute onset of sarcoidosis with EN, and
rapid resolution of the disease (46). In a study of 140 sarcoidosis patients
followed up for five years outcome was good in patients with initial EN
and stage-I or stage-II radiographic changes. Patients with extrathoracic
lesions experienced slightly worse courses of disease. Eight patients had
stage-III changes in their chest radiographs. One of these patients died.
Two experienceded slight improvement in lung- function test results. The
others appeared to have irreversible pulmonary lesions (8).
Four of 356 sarcoidosis patients died during the period of observation.
The overall mortality rate was 1.5%, however, in the group with initial
stage-III changes the mortality rate was 25% (9).
In 571 sarcoidosis patients who included 37 patients of more than 65
years of age, the improvement rate in the elderly during five years of follow-
up was lower than in younger patients but the difference was not statistically
significant (55).
2.3.3. Outcome in sarcoidosis in Hokkaido
Several surveys have been performed in Japan in relation to the course of
and outcome in sarcoidosis (56, 57, 58, 59).
Yamamoto et al. followed up 775 sarcoidosis patients following them
for at least 3 years to asses whether there was a relationship between the
clinical picture on presentation and outcome. The most favourable
prognostic factors were age under 29 years, absence of subjective symptoms,
absence of lung, eye and skin lesions, and normal serum gamma-globulin
levels. A combination of age under 29 years and absence of eye lesions
was the most favourable situation, seen in 260 patients. All sarcoidosis
lesions disappeared within two years in 70% of these patients (56).
Izumi reported on 61 of 153 sarcoidosis patients from Kyoto observed
from 1981-1985. Fifty per cent of patients had eye symptoms, 13% respiratory
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symptoms. Sixty-four percent of patients had stage-I changes in their chest
radiographs, 20% stage-II and 15% stage-III. The poorest outcome was
seen in patients with symptoms and stage-III lesions in their chest radio-
graphs or extrathoracic lesions on presentation with the disease (58).
Nagai et al. examined clinical profiles on presentation in 337 patients
with pulmonary sarcoidosis followed up for more than 10 years. Advanced
age, symptoms on presentation, parenchymal shadows and corticosteroid
treatment were associated with less favourable outcomes. (59).
2.4. Familial sarcoidosis
2.4.1. Familial sarcoidosis throughout the world
Martenstein was the first to suggest the possibility of a hereditary factor in
sarcoidosis (60). Since then, some 500 cases of sarcoidosis with familial
connections have been reported. The prevalence of familial sarcoidosis has
varied in studies from 1.7% to 14% (61, 62). In most studies sibling-
sibling and parent-offspring relationships have been most prevalent (61,
63, 64).
Jörgensen surveyed 2471 patients and found 40 close relatives with the
same disease, indicating a hereditary background (62). A report on outbreak
of sarcoidosis in the Isle of Man shows that inheritance may have played a
role (65).
Wiman, in Sweden, surveyed 299 sarcoidosis patients, including 20
familial cases. The prevalence of familial sarcoidosis was 6.9%. He
concluded that genetic drift may be of importance (66).
Sharma et al. surveyed 687 patients with sarcoidosis in Los Angeles
and London. The series included Caucasians, Afro-Americans and
Caribbeans. They found 16 families in which there were two or more
sarcoidosis cases (33 cases in all) and noted that certain ethnic groups
were more prevalent (especially Afro-Americans) but that genetic
susceptibility also played a role (67).
2.4.2. Familial sarcoidosis in Finland
In Finland there have been only a few studies on heredity in sarcoidosis.
Elo (9) and Poukkula et al. (10) studied sarcoidosis epidemiologically in
two areas. The prevalences of familial sarcoidosis in these areas were 3.4%
and 6%.
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Selroos et al. reported identical twin sisters with clinically almost identical
sarcoidosis (stage-II pulmonary changes and hypercalciuria) despite their
having lived for many years in different areas of Finland. One had received
two courses of corticosteroid treatment. Both twins recovered within similar
times (68).
2.4.3. Familial sarcoidosis in Hokkaido
In Japan, Kawabe et al. reported a mother-daughter pair who suffered from
sarcoidosis nine years apart. The authors suggested that inhaled agents
and genetic factors could have led to the sarcoidosis (69).
Ito et al. surveyed 2700 consecutive patients with sarcoidosis, and found
16 familial cases, giving a prevalence of familial sarcoidosis of 0.6% (70).
In 1977, in Furano, Hokkaido, an outbreak of 33 sarcoidosis cases was
reported, giving a very high prevalence of sarcoidosis, for Japan, of 140
per 100,000. Of the 33 cases 29 were in 14 families. Both genetic and
environmental factors were suspected to lie behind the high prevalence
(27).
In 1992, in a study of 80 familial sarcoidosis cases, a brother-sister
relationship was commonest, followed by a parent-child (mainly mother-
child) relationship (71).
2.5. Genetics of sarcoidosis
2.5.1. Genetics of sarcoidosis in general
For decades it has been suggested that genetic factors may predispose to
sarcoidosis and that such factors may determine the clinical picture of the
disease. Mechanisms of inheritance have been discussed. Jörgensen
suggested that sarcoidosis could be inherited as a multifactorial trait (62).
James et al. investigated nine sarcoidosis families in Great Britain. They
felt that the familial distribution of sarcoidosis within the nine families
was consistent with autosomal resessive inheritance (61).
Headings reported a series of 80 black patients with sarcoidosis,
including 11 families in which there have been two or more sarcoidosis
cases. They found support for the idea of a multigenic inheritance mode
(64). Maliarik et al. also found support for this idea in a study involving
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linkage analysis of major histocompatibility genes in familial sarcoidosis
(72).
The human leukocyte antigen (HLA) system has been found important
in relation to susceptibility to several other diseases. A number of studies
have been made of the relationships between HLA type and sarcoidosis.
Differences between ethnic groups have been found. In Germany an
association between HLA-DR5 and sarcoidosis has been reported (73), in
Turkey an association between HLA-A9 and -B5 and sarcoidosis (74). In
black populations associations between sarcoidosis and HLA-B7 (75),
between sarcoidosis and HLA-B15 (76) and between sarcoidosis and
HLA-Aw30 (77) have been reported. In contrast, Whitsett et al. found no
association between HLA type and sarcoidosis in Afro-American patients
(78).
In 1990 Lenhart et al. found negative associations between sarcoidosis
and HLA-Cw5 and -Cw7, suggesting that these HLA could protect against
sarcoidosis (79).
Persson et al. showed an association between HLA-A7 and sarcoidosis
patients with negative tuberculin-skin-test results and symptoms (80).
HLA type has been shown to have an association with the clinical picture
of and/or outcome in sarcoidosis more often than an association with
susceptibility to sarcoidosis.
An association between sarcoidosis arthritis, with or without EN, and
HLA-B8/DR3 has been reported by a number of investigators (81, 82, 83,
84, 85). Both HLA-B8 and -DR3 have shown to be associated with a good
outcome in sarcoidosis (81, 86). In a Swedish study of 122 Scandinavian
sarcoidosis patients, those with the HLA-DR17(3) (previously known as
HLA-DR3) phenotype had significantly better outcomes than the others.
On the other hand, in patients with the HLA-DR14(6) and -DR15(2)
phenotypes there was an association with chronic sarcoidosis (87).
In a study in which two ethnic sarcoidosis groups (British and West
Indian) were compared a relatively high incidence of HLA-Cw7 in the
British sarcoidosis patients, and a correlation between good outcome and
HLA-B8, -Cw7 and -DR3 were found. In contrast, in West Indians a
relatively high incidence of HLA-DR7 was found. However, no association
between HLA type and clinical manifestations was demonstrable (88). Finco
et al. found an association between poor outcome and HLA-DR5, especially
in men (89). Studies on HLA and sarcoidosis are listed in Table V.
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Table V:
Worldwide studies on sarcoidosis and HLA.
Author(s) HLA type Associations with
Akokan et al. (1977) A1, B5 Susceptibility to sarcoidosis
Al-Arif et al. (1980) B15 Susceptibility to sarcoidosis
Berlin et al. (1997) DR17(3) Good outcome
DR14(6), DR15(2) Chronic sarcoidosis
Brewerton et al.  (1977) B8 Arthritis with or without EN
Finco et al. (1991) DR5 Poor outcome (in men)
Gardner et al. (1984) Cw7 Susceptibility to sarcoidosis
Cw7, B8, DR3 Good outcome
DR7 Susceptibility to sarcoidosis
Guyatt et al. (1982) B8 Arthritis with or without EN
Hedfors & Lindström (1983) B8 Arthritis with or without EN
Kremer (1986) DR3 Arthritis with or without EN
Lenhart et al. (1990) Cw5, Cw7 Protection against sarcoidosis
McIntyre et al. (1977) B7 Susceptibility to sarcoidosis
Neville et al. (1980) B8 Arthritis with or without EN
Newill et al. (1983) Aw30 Susceptibility to sarcoidosis
Nowack & Goebel (1986) DR5 Susceptibility to sarcoidosis
Persson et al. (1975) A7 Negative tuberculin skin test
Smith et al. (1981) B8 Arthritis with or without EN
Whitsett et al. (1983) - None
2.5.2. Genetics of sarcoidosis in Finland
A recent report on HLA types in the Finnish population showed that the
commonest were A2, A3, B35, B7, DR1, DR2, Cw7 and Cw3. B8 was also
fairly common, as in other Nordic countries (90).
Grönhagen-Riska et al. investigated a familiy with sarcoidosis and
Crohn’s disease and found the haplotypes B8/DR3 in all affected patients
(91).
There are no other reports regarding HLA types in Finnish sarcoidosis
patients.
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2.5.3. Genetics of sarcoidosis in Hokkaido
In the1980s several studies on HLA types in sarcoidosis were published in
Japan. In the studies by Kunikane et al. (92) and Abe et al. (93) the
commonest HLA types in sarcoidosis populations were DRw52 and DRj5.
The presence of HLA-DRj5 was shown to be associated with a poor outcome
(93). Ina et al. showed that patients with HLA-DRw52 and-DR5 had earlier
onset of sarcoidosis but a better outcome than patients with HLA-DRw8
(94).
Tachibana et al. also found that HLA-DRw52 was common in Japanese
sarcoidosis patients but -B8 and -DR3 were rare (95). Ishihara et al. found
no significant correlations on analysing HLA-DM polymorphism and
allelic variation of the TAP2 gene in relation to susceptibility to sarcoidosis
(96, 97).
2.6. Angiotensin-converting enzyme
gene polymorphism and sarcoidosis
The angiotensin-converting enzyme (ACE) gene is polymorphic. A non-
sense DNA fragment can be present or absent (98). The polymorphism is
located in intron 16. ACE itself therefore does not differ in relation to
genotype but polymorphism accounts for 47% of total enzyme levels (98).
The genotype is divided into three types: insertion homozygotes (II), deletion
homozygotes (DD), and heterozygotes (ID). Serum ACE activity has been
found to be significantly higher in DD individuals than in II individuals, in
healthy control subjects and in patients with sarcoidosis (99-101). No
significant difference has been found in allele distribution between controls
and sarcoidosis patients (99-101). ACE polymorphism therefore does not
predispose to the disease.
There are differences in prevalences of the D and I alleles between
ethnic groups (98-102). This may be interesting from a sarcoidosis
epidemiological point of view.
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2.6.1. Angiotensin-converting enzyme gene polymorphism
and sarcoidosis in Finland and Japan
There have been no studies on the ACE gene polymorphism in the Finnish
population.
In caucasians, the D allele appears dominant. I/D ratios of 0.41/0.59
(98), 0.45/0.55 (102) and 0.49/0.60 (100) have been reported.
In Japanese individuals, the I allele is dominant: I/D ratios of 0.67/0.33
in control subjects and 0.61/0.39 in sarcoidosis patients have been reported
by Furya et al. (101), and 0.65/0.35 in controls and 0.62/0.38 in sarcoidosis
patients by Tomita et al. (99). There are also some indications that Japanese
sarcoidosis patients with the ACE DD genotype have a more prolonged
disease than patients with other genotypes (99).
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3. AIMS OF STUDY
Literature reports indicate that incidences and prevalences, clinical pictures
of and outcomes in sarcoidosis differ between Finland and Japan. The
overall aim of the study was to investigate sarcoidosis in two well-defined
populations of similar sizes living in similar climatological enviroments
(the Mjölbolsta Hospital cathment area in southern Finland, and Hokkaido,
a northerly island of Japan), in which, in addition, incidences and
prevalences of tuberculosis were similar during the study period, to
determine whether reported differences were real or could be explained by
differences in classification, terminology or diagnostic procedures.
Aim of Study I: To asses whether reported differences in prevalences and
incidences of sarcoidosis between Finland and Hokkaido were real.
Aim of Study II: To describe and compare the clinical pictures of sarcoidosis
in Finland and Hokkaido.
Aim of Study III: To compare the prognoses in pulmonary sarcoidosis in
Finland and Hokkaido.
Aim of Study IV: To determine incidences and prevalences of familial
sarcoidosis in Finland and Hokkaido and to analyse types of associations
reported.
Aim of Study V: To describe the HLA pattern in Finnish sarcoidosis patients
and compare it with the HLA pattern in sarcoidosis patients in Japan.
Aim of Study VI: To determine ACE genotypes in Finnish sarcoidosis
patients and to evaluate prognoses in patients with different ACE genotypes.
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4. SUBJECTS AND METHODS
4.1. Study populations and
designs of studies I-VI
Study I
To calculate incidences and prevalences of sarcoidosis in Finland and
Hokkaido, the following procedures were performed: In 1984 a seventh
nationwide survey on sarcoidosis in Japan was carried out by the Intractable
Disease Research Committee of the Japanese Ministry of Health and
Welfare. The survey involved of two stages. In the first, hospitals with 200
or more beds were asked to report numbers of sarcoidosis patients visiting
their hospitals in 1984. In the second stage physicians in the hospitals
were asked to provide clinical information about individual patients with
verified diagnoses of sarcoidosis. Raw data stored by the Japan Sarcoidosis
Committee on magnetic tape were made available to the study group.
In Finland, hospitals are requested to report on all patients discharged.
Permission was obtained to use official health statistics for 1984 which
included a diagnosis of sarcoidosis (1969 WHO codes 135,97 and 135,99)
and patients  birth dates. All hospitals in which patients with proven
sarcoidosis had been seen in 1984 were approached. After obtaining
permission, hospital records were evaluated using the Japanese case-report
forms as a model. In all, 99.5% of patient records were made available.
Both series of patients included both hospitalized and out-patients. However,
in 1984 most patients with suspected sarcoidosis were hospitalized for
diagnostic purposes.
In Hokkaido, Finnish members of the project team made themselves
acquainted with the Japanese classification of and diagnostic criteria for
sarcoidosis. The same criteria were then applied and identical information
collected in both countries. Diagnosis was to be based on one or other of the
following criteria: a) a chest-radiography finding of BHL with or without
parenchymal shadows and a histological finding in at least one organ
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showing noncaseating epithelioid cell granulomas; b) a histological finding
as above in combination clinical symptoms or signs compatible with
sarcoidosis, but a normal chest radiograph; c) a chest-radiography finding
with BHL, with or without parenchymal shadows and a typical clinical
picture; d) symptom-free patients with typical chest-radiography findings
exhibiting gradual spontaneous regression during a sufficiently long follow-
up period and exclusion of other lung diseases. Similarity of interpretation
of chest radiographs in Finland and Japan was carefully checked.
Prevalence was defined as number of cases with active sarcoidosis during
1984, irrespective of year of diagnosis. Incidence was number of new cases
diagnosed in 1984.
In relation to Hokkaido series the number of patients was estimated
using established methods (103, 104).
Study II
To compare the clinical pictures of sarcoidosis in Finland and Hokkaido two
hospital materials were evaluated:
During the period 1955-1987, 571 patients with sarcoidosis were seen at the
Mjölbolsta Hospital, Finland. From 1964 to 1988, 686 sarcoidosis
patients were admitted to the Sapporo Hospital of the Hokkaido Railway
Company. Within their respective areas these two hospitals have been the
units to which patients with suspected sarcoidosis have been referred
throughout the years concerned.
To facilitate comparison of the two populations, two of the Finnish
investigators participated for three months in clinical work in Sapporo.
This background allowed patient data to be evaluated identically in Finland
and Japan, focusing on diagnostic criteria, symptoms and findings ont
diagnosis (thoracic and extrathoracic), and on results of biopsy procedures
and laboratory investigations.
The diagnostic criteria used were the same as in the 1984 incidence and
prevalence in Finland and Hokkaido.
Acceptability of diagnosis of sarcoidosis: Three hundred and seventy-eight
of the 571 Finnish patients (66%) and 293 of the 686 Hokkaido patients
(43%) had biopsy-proven diagnoses of sarcoidosis. Diagnosis of sarcoidosis
in relation to the other patients was based on clinical picture and chest-
radiography findings. Diagnoses of sarcoidosis in Japanese patients with
only eye involvement could be accepted if there were also concomitant
increase in serum ACE activity and/or lysozyme concentrations. All
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Japanese sarcoidosis patients had been  routinely  checked by an
ophthalmologist. Numbers of patients with sarcoidosis defined according to
the various diagnostic criteria are shown in Table VI.
Results of tuberculin skin tests were also compared. In Finland titrated
PPD skin tests were performed, starting with 1 or 2 TU. If the test was
negative, 10 TU were used. In Japan 0.05µg of PPD in a 1:2000 solution
(corresponding to 2.5 TU) was the initial concentration used followed by
0.25µg, if necessary (12.5 TU). A 5 x 5 mm induration was considered to
represent a positive reaction.
Results of biochemical laboratory tests such as concentrations of serum
lysozyme (S-LZM), serum calcium (S-Ca), total serum proteins (S-prot)
and serum gamma-globulin (S-γ-glob), and serum ACE and serum alkaline
phosphatase (S-Afos) activities were recorded. The peripheral blood picture,
including haemoglobin level (B-Hb), leukocyte count (B-leuk), lymphocyte
count (B-lymph), thrombocyte count (B-thromb) and erythrocyte
sedimentation rates (ESR) were checked. Numbers of values within and
outside corresponding reference ranges were noted. Laboratory test results
for the two series were transformed to standard units before statistical
analysis. Laboratory test methods in the two countries were, however, not
compared.
Results of lung-function tests recorded related to forced vital capacity
(FVC), forced expiratory volume in one second (FEV1) and diffusion
capacity for carbon monoxide (DLco).
Study III
To allow assesment of differences in prognoses in pulmonary sarcoidosis
in Finland and Japan, data relative to of 563 Finnish and 579 Hokkaido
patients who had been hospitalized because of pulmonary sarcoidosis were
carefully re-evaluated. Only 437 Finnish and 457 Japanese patients with
initial chest radiographic changes and positive biopsy findings were selected
for further review. It should be noted that the patients included in this
comparison were not identical with those in studies I and II. Characteristics
of these patients are recorded in Table VII. Factors such as age, sex, initial
chest-radiographic finding, and presence or absence of extrapulmonary
lesions were investigated. Five-year follow-up data were recorded and
differences over time between Finnish and Japanese patients were assessed
on a yearly basis.
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Table VI:
Numbers and percentages of patients according to diagnostic criteria in
Finnish and Hokkaido hospital series.
Hospital HP+ HP+ HP- HP- HP- Total
CR+ CR- CR+ CR- CRm
CP+ CP+ CP+ CP+ CP+
Mjölbolsta 374 (65%) 4 (1%) 188 (33%) 5 (1%) 0 571 (100%)
Sapporo 268 (39%) 25 (4%) 277 (40%) 97 (14%) 19 (3%) 686 (100%)
HP= Histopathology, CR= Chest radiograph, CP= Clinical picture, m= missing
Table VII:
Characteristics of Finnish and Japanese patients with biopsy-proven
radiographic pulmonary sarcoidosis
Finland Hokkaido
No. of patients Percentage No. of patients Percentage
iobox.fisaijai
Total no. of  patients 437 100 457 100
Female 254 58.1 234 51.2
Male 183 41.9 223 48.8
Mean age, years (SD) 41.9 (12.9) 28.4 (13.7)
Stage I 191 43.7 309 67.6
Stage II 186 42.6 125 27.4
Stage III 58 13.3 23 5.0
Stage IV 2 0.4 0 0
Erythema nodosum 101 23.1 0 0
Extrapulmonary
sarcoidosis* 197 45.0 244 53.4
Symptom-free
patients 215 49.3 261 57.1
* Excluding patients with erythema nodosum
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Study IV
To determine the incidence and prevalence of familial sarcoidosis in Finland
and Hokkaido, the 1984 series and the two hospital series from Finland
and Hokkaido were used. Relatives having the same disease were identified,
and the nature of the relationship noted. Clinical pictures of and outcomes
in familial and non-familial cases in the two areas were compared.
Study V
The HLA pattern in Japanese sarcoidosis patients is known (94, 95). To
determine the HLA pattern in Finnish sarcoidosis patients we studied 20
consecutive patients (9 men and 11 women) with sarcoidosis in the
Mjölbolsta Hospital. Sixteen had positive biopsy findings showing non-
caseating granulomas. Diagnosis in the other 4 patients was based on typical
clinical pictures (with EN), chest radiography findings and biochemical
results (high S-ACE activity and/or high S-LZM concentrations). All
patients exhibited changes in their chest radiographs on presentation: nine
exhibited stage-I changes, seven stage-II changes and four had stage-III
changes. Duration of sarcoidosis at the time of investigation varied from
0.5 to 12 years. Fourteen of the patients were still suffering from active
disease.
We used published data relating to 10,000 subjects in the national bone-
marrow-donor registry (90) for relating porposes. Both controls and patients
were representative of the whole country because of the homogeneity of
the Finnish population.
Associations between HLA types and the commonest symptoms
(dyspnoea, erythema nodosum), chest-radiographic findings and good or
less favourable outcome were also evaluated. For HLA typing 30-ml samples
of heparinized peripheral blood were obtained. Mononuclear cells were
then isolated using Lymphoprep (Nyegaard and Co A/S, Oslo, Norway)
density-gradient centrifugation. HLA class-I and class-II were determined
using standard microlymphocytotoxicity methods. The local panel of
antisera were complemented with commercial sera from Biotest (Dreieich,
Germany) and results confirmed using a panel from the Eleventh
International Histocompatibility Workshop. HLA loci A, B, C, DR and DQ
were studied. However, because of the small number of patients antigen
subtypes were not included in the final analysis. The 50 broad specifities
determined were: HLA-A 1, 2, 3, 9, 10, 11, 19, 28; HLA-B 5, 7, 8, 12, 13,
14, 15, 16, 17, 18, 21, 22, 27, 35, 37, 40, 47, w4, w6; HLA-C 1 to 7;
HLA-DR 1 to 10 plus 51, 52, 53 and HLA-DQ 1 to 4.
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Left-over cells were stored for subsequent DNA extraction. After
analysing serological results Cw* alleles were determined using the PCR-
SSP method employed at the Twelvfth International Histocompatibility
Workshop, with purchased primers (Merck, through Kebo Lab Co, Helsinki)
made like those based on and supplied for the Workshop [Bunce & Welsh
(105)]. To exclude the possibility of inadequacies in the HLA-typing
serological and DNA typing were performed in 88 routinely HLA-typed
miscellaneous patients.
Sudy VI
Whole-blood samples were obtained from 59 Finnish sarcoidosis patients
and 70 control subjects. The sarcoidosis blood samples were taken from
consecutive, known patients (followed up for one to 23 years) visiting the
hospital’s out-patient department for scheduled visits. The blood samples
were stored at -70° C until shipped to Sapporo, Japan, for analysis.
Patient characteristics on diagnosis according to ACE genotype are
shown in Table VIII. There were 42 female and 17 male patients. All
Table VIII:
Patient characteristics on diagnosis according to ACE genotype.
Genotype II Genotype ID Genotype DD Total
Women 7 23 12 42
Men 2 9 6 17
Biopsy + 6 20 15 41
Steroid treatment 5 19 11 35
Pulmonary findings:
Stage 0 0 1 1 2
Stage I 5 17 5 27
Stage II 2 10 8 20
Stage III 2 4 3 9
Extrapulmonary
findings:
Erythema nodosum 3 4 4 11
Peripheral lymph node 0 7 2 9
Skin 2 6 3 11
Eyes 1 7 2 10
Other* 4 7 6 17
Hypercalcemia 1 3 1 5
* Including spleen, liver, kidney, heart, CNS and parotid gland
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exhibited chest radiographic changes. Twenty-seven patients had radio-
graphic stage-I lesions, 20 patients stage-II lesions. Thirty-one patients
(53%) had extrapulmonary sarcoidosis manifestations other than EN, which
had occurred in 11 patients. Detection of ACE-gene polymorphism: A 287
base-pair I/D polymorphism in intron 16 of the ACE gene was examined
using the polymerase chain reaction (PCR), as previously described (101).
Briefly, two primers, sense oligo 5‘CTGGAGACCACTCCCATCCTTTCT3‘
and anti-sense oligo 5‘GATGTGGCCATCACATTCGTCAGAT3‘, were
synthesized to amplify the polymorphic fragment. Reactions were performed
using 10 pmol of each primer in a final volume of 50µl containing 100 ng
of genomic DNA, 3 mM MgCl
2
, 50 mM KCl, 10 mM Tris-HCl, pH 8.4,
0.1 mg/ml gelatin, 0.5 mM of each deoxynucleotide triphosphate (dNTP),
1 unit of Taq polymerase (Perkin Elmer Cetus, Norwalk, USA). The DNA
was amplified for 30 cycles as previously described (106). PCR products
were subjected to electrophoresis in agarose gels and visualized by the sizes
of bands, as previously described (107).
Determination of outcomes in sarcoidosis: Outcomes were evaluated
after observation periods of one, 2, 3, 5 and more than five years following
diagnosis. Outcome was classified as good if the chest radiograph had
become normal within 2 years, no signs of extrapulmonary sarcoidosis
were detectable, and biochemical markers of sarcoidosis activity (S-ACE,
S-LZM, serum ß
2
-microglobulin concentrations and S- and U-Ca levels)
were normal. Outcome was classified as poor if after 5 years of follow-up
infiltrates remained visible on chest -radiography, and impaired lung
function (FVC, DLco) and/or active extrapulmonary disease in combination
with increased levels of one or more biochemical markers of sarcoidosis
activity had been found. The outcome in patients who did not fulfil the
above criteria was classed as intermediate. Such patients might have achieved
a normal status after 2 to 5 years of follow-up, or infiltrates might have
remained visible on chest radiography with borderline signs of disease
activity.
4.2. Statistical methods
Study I
Distributions of frequencies and percentages were calculated for all
qualitative variables and other variables divided into classes.
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Comparison between the Finnish and Hokkaido series with respect to
class-divided variables was undertaken using cross-tables and calculating
x2-values. Significances of differences were tested using the x2 -test.
A p value of less than 0.01 was taken to indicate significance. The same
methods were used to compare groups of patients with respect to distribution
of quantitative and class-divided variables.
Arithmetic means and standard deviations were calculated for quantitative
variables. Differences between means were tested using the t-test and
analysis of variance. A p value of less than 0.01 was taken to indicate
significance. Adjusted incidences and prevalences were calculated taking
the Finnish population in 1984 as the standard population.
Adjusted incidences and prevalences for Hokkaido were derived from
the age-adjusted Finnish population multiplied by age-adjusted rates in
Hokkaido, divided by the total Finnish population.
Study II
Frequency distributions were calculated for all qualitative variables and
for other variables divided into classes. In some cases distributions were
described using charts. Dependence between variables was assessed by
calculating contigency coefficients. The chi-squared test was used to test f
or independence between variables, and in comparing groups of patients
with respect to qualitative variables.
Quantitative variables were described by calculating the arithmetic
means and standard deviations. Distributions of quantitative variables were
also described by drawing histograms.
Since reference values were different in the two hospitals, laboratory
test results were transformed to facilitate comparison. Laboratory values
(expressed in SI units) were standardized relative to individual reference
ranges by deducting the low reference limit from the value found. The
standardized value is independent of any units. Unit were subsequently
restored expressing reference ranges in international units. All statistical
comparisons were made using the transformed values, in the case of
ESR.
Differences between groups were tested for significance using Student’s
t-test and one-way analysis of variance. Dependences between quantitative
variables were studied and significances tested using the Pearson correlation
coefficient. The significance level used in significance testing was 0.01.
Distributiosn of symptoms in the various age groups were tested using
Spearman’s rank-correlation test.
38
SUBJECTS AND METHODS
Study III
Frequency distributions were calculated for all qualitative variables and
for other variables divided into classes. In some cases distributions were
described by means of charts.
Dependence between qualitative variables was studied by preparing
contingency tables and computing Pearson contigency coefficients. The
chi-squared test was used to test for independence between variables, and
comparing groups of patients in respect of qualitative variables.
Quantitative variables were described by calculating the arithmetic
means and standard deviations. Distributions of quantitative variables were
also studied by means of histograms.
Differences between groups were tested for significance using the t-test
and one-way analysis of variance. Dependences between quantitative
variables were studied and the significances tested using the Pearson
correlation coefficient. Contingency tables and the chi-squared test were
used to study how the results of different tests could be used to predict the
development of sarcoidosis after diagnosis. A p value less than 0.01 was
considered to indicate significance.
Study IV
Familial and non-familial cases in Finland and Hokkaido were compared
using the chi-squared test, the Mann-Whitney U-test and Student’s t-test.
Study V
The chi-squared test was used in comparing the HLA frequencies between
patients and controls; p values were multiplied by 41 (the number of HLA
specificities compared) to obtain a corrected p value (p
c
).
Fisher’s exact test was used to find associations between HLA and clinical
parameters. Odds ratios were calculated using the formula RR = ad/bc,
where a = number of patients with given HLA antigen, b = number of
patients without it, c = number of control subjects with it and d = number
of controls without it.
Study VI
Significances of differences in allele and genotype frequencies between
control subjects and sarcoidosis patients were tested using chi-squared
test. Odds ratios were calculated to estimate relative risk of sarcoidosis,
and analyses were carried out using logistic regression models adjusted
for sex and/or age.
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5. RESULTS
5.1. Incidences and prevalences of sarcoidosis
in Finland and Hokkaido, Japan.
(Study I)
Incidences and prevalences of sarcoidosis
Evaluation of Finnish statistics for 1984 showed that there were 1378 patients
who met the diagnostic criteria for sarcoidosis. Five hundered and fifty-
seven had been diagnosed in 1984. Sixty-two per cent of all Finnish patients
had had histological verification of their disease. On the basis of these
numbers the crude prevalence of sarcoidosis in Finland in 1984 was 28.2
per 100,000 and the annual incidence 11.4 per 100,000. Since all Finnish
hospitals with sarcoidosis patients in 1984 were approached and the
response rate was almost 100%, the figures given must be very close to
the true incidence and prevalence of sarcoidosis in Finland.
In the Hokkaido survey in 1984, 288 patients met the diagnostic
criteria for sarcoidosis. Forty-six were diagnosed in 1984. Of the Hokkaido
patients, 78.4% (on the basis of 208 patients for whom data was available)
had histological evidence of the disease.
The crude prevalence of sarcoidosis in Hokkaido was 5.1 per 100,000
and the annual incidence 0.8 per 100,000. As only hospitals with 200 or
more beds had been approached and the response rate was 53.5%, true
incidence and prevalence figures had to be estimated. Estimated true
prevalence was 7.2 per 100,000 and incidence 2.8 per 100,000.
Age-adjusted prevalences and incidences in Finland and Hokkaido are
shown in Fig. 1 and 2. The prevalence and the incidence were significantly
higher for Finland.
Age-adjusted prevalences and incidences are shovnn in Table IX. The
difference in prevalence as well as in incidence is high between Finland and
Hokkaido the age-adjusted figures are similar to the crude figures.
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Table IX:
Age-adjusted incidences and prevalences of sarcoidosis in Finland and
Hokkaido
Finland Hokkaido
Incidence per 100,000 Male 9.0 0.8
Female 13.8 0.9
Total 11.5 0.9
Prevalence per 100,000 Male 22.0 4.9
Female 34.4 7.0
total 28.4 5.0
Fig. 1:
Age-adjusted prevalences of sarcoidosis in Finland and Hokkaido in 1984.
Fig. 2:
Age-adjusted incidences of sarcoidosis in Finland and Hokkaido in 1984.
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Sex and age distributions
The number of female patients in the Finnish series was 868 (63%), in
Hokkaido 193 (67%). The male/female ratios were therefore similar. The
Hokkaido patients were younger at the time of diagnosis. Mean age (SD)
was 40.2 (16.1) years as compared with 45.0 (13.7) years for the Finnish
patients. This difference is statistically significant (p < 0.001). Median ages
were 38 and 44 years, respectively. Age distributions are shown in Fig. 3.
Fig. 3:
The age distributions of sarcoidosis patients in Finland and Hokkaido in
the 1984 surveys.
5.2. Mode of presentation of sarcoidosis
in Finland and Hokkaido (Study II)
Presenting symptoms
Fifty per cent of Finnish patients and 51% of Hokkaido patients were
symptom-free.
In symptomatic patients in Finland the commonestt symptoms were
cough [189 patients (21%)], fatigue [118 (21%)], EN [102 (18%)],
arthralgia [89 (16%)] and chest pain [67 patients (12%)]. Only 27 (5%)
had eye symptoms.
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In Hokkaido, the main presenting symptoms were eye symptoms [245
patients (41%)], enlarged peripheral lymph nodes [18 patients (4%)], cough
[14 patients (3%)] and fever and skin symptoms [10 patients (2%).]
Symptoms leading to a diagnosis of sarcoidosis are recorded in Fig. 4. In
Finland, the percentage of symptom-free patients per age group increased
significantly with age (p < 0.001) The opposite was found in Hokkaido
(p < 0.001) (Table X).
Fig. 4:
Presenting symptoms of sarcoidosis patients in the Finnish (Mjölbolsta)
and Hokkaido (Sapporo) hospital series.
X) Not recorded, *** < 0.001
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Table X:
Numbers of sarcoidosis patients in Finnish (A) and Hokkaido (B) hospital
series grouped by age and sex, and numbers of symptom-free patients at
time of diagnosis.
A:
Age group Male Female Total Symptom-free Percentage of
patients symptom-free
patients
Years No. (%) No. (%) No. (%) No.
0 - 9 0 (0) 0 (0) 0 (0) 0 0
10 - 19 1 (0.5) 2 (0.5) 3 (0.5) 2 67
20 - 29 54 (23) 51 (15) 105 (18) 24 23
30 - 39 100 (43) 83 (25) 183 (32) 86 47
40 - 49 48 (20) 80 (24) 128 (22) 80 63
50 - 59 19 (8) 64 (19) 83 (15) 48 58
60 - 69 10 (4) 44 (13) 54 (9) 30 56
70 - 3 (1) 12 (3.5) 15 (2.5) 14 93
Total 235 (100) 336 (100) 571 (100) 284 50
B:
Age group Male Female Total Symptom-free Percentage of
patients symptom-free
patients
Years No. (%) No. (%) No. (%)  No.
0 - 9 7 (2) 5 (1) 12 (2) 8 67
10 - 19 88 (28) 83 (22) 171 (25) 96 56
20 - 29 149 (48) 104 (28) 253 (37) 121 48
30 - 39 26 (8) 45 (12) 71 (10) 23 32
40 - 49 19 (6) 59 (16) 78 (11) 26 33
50 - 59 13 (4) 51 (14) 64 (9) 16 25
60 - 69 7 (2) 22 (6) 29 (4) 6 21
70 - 1 (0.5) 7 (2) 8 (1) 4 50
Total 310 (100) 376 (100) 686 (100) 300 44
Age and sex distribution and smoking habits
On diagnosis the mean age (SD) of Finnish sarcoidosis patients was
47 (14.5) years as compared with 30 (15.4) years in Hokkaido (p < 0.001).
There was a female predominance in both series: 59% in Finland, 55% in
Hokkaido.
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In patients below 40 years of age, there were significantly more men
(p < 0.001) in both series: 67% of all male patients versus 41% of all female
patients in the Finnish series, 86% of all male patients versus 63% of all
female patients in Hokkaido.
Twenty-eight per cent of the Japanese patients were smokers as
compared with only 16% of the Finnish patients (p < 0.001).
Intrathoracic and extrathoracic findings
On diagnosis chest-radiography findings were different in the two series.
In the Finnish series, stage-I changes were found in 48% of patients as
compared with 57% in the Hokkaido series (p < 0.01). Stage-II lesions
were seen in 39% of Finnish patients and 20% of Hokkaido patients.
Stage-III changes were found in 12% of Finnish patients and 5% of
Hokkaido patients (p < 0.001). On diagnosis, only 1% of Finnish patients
but 19% of Hokkaido patients had normal chest radiographs. The Hokkaido
patients had only eye and/or skin lesions on presentation. Distributions of
chest-radiography findings are shown in Fig. 5.
Fig. 5: Chest radiographic findings on diagnosis of sarcoidosis in the
Finnish (Mjölbolsta) and Hokkaido (Sapporo) series.
On diagnosis the commonest extrapulmonary lesions in the Finnish
series were peripheral lymphadenopathy [140 patients (25%)], EN
[73 patients (13%)], eye lesions [39 patients (7%)] (most often diagnosed
by an ophthalmologist), skin lesions [28 patients (5%)] and splenic
involvement (fine-needle aspiration biopsy) [25 patients (4%)].
** p < 0.01, *** < 0.001
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In Hokkaido, the commonest extrapulmonary finding on presentation was
an eye lesion, seen in 344 patients (50%). The difference in prevalence of
ocular lesions between Finnish and Hokkaidoan patients was significant
(p < 0.001). The second commonest extrapulmonary lesion in Hokkaido
was lesions the of peripheral lymph nodes, in 137 patients (20%), similar to
the Finnish figures. The other lesions reported in Hokkaido were skin lesions
[47 patients (7%]), myocardial lesions [31 patients (5%)], findings in salivary
glands [25 patients (4%)] and in the nervous system [19 patients (3%)].
EN was found in only three patients. The difference in prevalence of EN
between the Hokkaidoan and Finnish series was statistically significant
(p < 0.001). Extrapulmonary findings are summarized in Fig. 6.
Fig. 6: Extrapulmonary findings of sarcoidosis in the Finnish (Mjölbolsta)
and Hokkaido (Sapporo) hospital series.
Tuberculin skin test
In Finland 245 patients tested positive for 1 or 2 TU (43%), and 91 patients
tested positive for 10 TU (16%). Two hundered and eight patients tested
negative for 10 TU (36%). No testing was undertaken in 27 patients.
The Hokkaido patients were divided into skin-test positive (189 patients,
28%) and skin-test negative (431 patients, 63%) depending on their
reactivity to 12.5 TU. Sixty-six Hokkaido patients were not tested.
*** p < 0.001, 1) Positive fine-needle aspiration biopsies
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RESULTS
Fig. 7: Results of tuberculin skin tests on diagnosis of sarcoidosis in the
Finnish (Mjölbolsta) and Hokkaidoan (Sapporo) hospital series.
The number of skin-test-negative patients was higher in Hokkaido than
in Finland but the difference was not statistically significant. Results of the
tuberculin skin tests on diagnosis are summarized in Fig. 7.
Lung function and clinical laboratory tests
Forced vital capacities (FVC), forced expiratory volumes in one second
(FEV1) and diffusion capacities (DLco) as percentages of predicted normal
values (mean, SD) were normal in both series; FVC 98% (16.6%) in Finland
and 101.6% (16.8%) in Hokkaido; FEV1 96.0% (18.8%) in Finland and
83.4% (9.1%) in Hokkaido; and DLco 94.4% (16.8%) in Finland and 88.6%
(34.0%) in Hokkaido. The difference in FEV1 values between the two
series is statistically significant (p < 0.001) but the differences in FVC and
DLco values between are not. The spirometric reference values have not
remained the same over time, in Finland or Hokkaido.
In clinical laboratory test results the following statistically significant
differences were found in relation to mean values between the two series:
the Finnish mean values for ESR, S-ACE, S-prot and S-Afos were higher
than the Hokkaido mean values (p < 0.0001 for each). Hokkaido means
were higher for S-LZM (p < 0.0001) and S-Ca (p < 0.001). No statistically
significant differences were found in relation to haemoglobin levels and blood
leukocyte counts. Thrombocytes were counted in only a few Hokkaido
patients.
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5.3. Outcome in pulmonary sarcoidosis
in Finland and Hokkaido (Study III)
The results of the five-year follow-up study of 437 Finnish and 457
Hokkaido biopsy-proven sarcoidosis cases with pulmonary sarcoidosis are
presented in terms of percentages of normalized chest radiographs.
All patients
Percentages of normalized chest radiographs in the two series of patients
with biopsy-proven sarcoidosis are shown in Table XI and Fig. 8. Within
one year 46% of Japanese patients, but only 16% of Finnish patients had a
normal chest radiographs. After five years of follow-up the corresponding
figures were 73% and 40%. The differences between the two series are
significant at all times (p < 0.001).
Fig. 8: Development of chest-radiography findings over 5 years after
diagnosis in all Finnish patients (Mjölbolsta Hospital) and Hokkaido
patients (Sapporo Tetsudo Hospital).
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Table XI:
Percentage of patients in Finnish and Hokkaido hospital series
experiencing normalization of chest radiographs during five years of
follow-up
     Follow-up (years)
No. of 1 2 3 4 5
patients
All patients
Finland 437 15.6*** 29.1*** 33.6*** 35.9*** 39.6***
Hokkaido  457 46.2 60.6 69.1 72.2 73.1
Female patients
Finland 254 16.9*** 30.3*** 35.8*** 39.0*** 42.1***
Hokkaido  234 44.9 58.1 66.2 70.1 70.9
Male patients
Finland 183 13.7*** 27.3*** 30.6*** 31.7*** 36.1***
Hokkaido  221 47.5 63.2 72.2 74.4 75.3
Age < 30 years
Finland  91 18.7*** 35.2*** 39.6*** 40.7*** 42.9***
Hokkaido 323 51.7 67.8 76.2 79.6 79.9
Symptom-free
patients
Finland 215 11.6*** 23.3*** 26.5*** 27.9*** 32.6***
Hokkaido  261 51.5 76.0 73.6 76.6 77.4
Erythema nodosum
patients
Finland 101
Pulmonary stage I 63 38.1 50.8 55.8 57.1 58.7
Pulmonary stage II 38 18.4 44.7 44.7 47.4 52.6
Hokkaido  0
Pulmonary stage I
Finland 191 16.2*** 31.0*** 35.2*** 40.1*** 46.5***
Hokkaido 309 59.2 68.3 72.2 75.1 75.7
Pulmonary stage II
Finland 186 11.8* 25.8*** 31.2*** 32.3*** 35.5***
Hokkaido 125 22.4 48.8 68.0 72.0 72.8
Pulmonary stage III
Finland 58 12.1 20.7 24.1 24.1 24.1
Hokkaido  23 0 21.7 34.8 34.8 39.1
Extrapulmonary
lesions present
Finland 197 13.7*** 25.9***  30.5*** 32.0*** 34.0***
Hokkaido  244 41.4 53.7 64.8 67.2 68.0
Statistically significant differences between the groups are shown by means of  asterisks:
*** = p < 0.001, * = p < 0.05
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Patients with initial stage-I radiographic findings
On diagnosis, 142 Finnish patients had stage-I lesions when patients with
EN were excluded. After a follow-up of one year 16% of patients had a
normal chest radiograph, after five years 47%. In Hokkaido, 309 patients
initially had stage-I lesions. After one year of follow-up 59% of the patients
had  developed  a normal chest radiograph, after five year 76%. The
differences in chest radiographic normalization rates between the two
series are significant (p < 0.001) at all times. Normalization of chest
radiographs in Finnish and Hokkaido patients with initial stage-I changes
during five year of follow-up is shown in Table XI and Fig. 9.
Fig. 9: Percentages of normalized chest radiographs in patients with
initial stage-I disease in Finnish and Hokkaido hospital patients,
including Finnish patients with EN, during five years of follow-up.
During the 5-year follow-up, 20% of Finnish patients and 14% of
Hokkaido patients with initial stage-I findings developed parenchymal
changes. Twelve per cent of Finnish stage-I patients and 5% of Hokkaido
patients still had parenchymal lesions after five years of follow-up.
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Patients with initial stage-II changes
One hundered and eighty-six of the Finnish patients and 125 of the
Hokkaido patients had initial stage-II changes in their chest radiographs.
After one years of follow-up 12% of Finnish patients and 22% of Hokkaido
patients (p = 0.013) had normal chest radiography findings, after five
years of follow-up, 36% of Finnish patients and 73% of Hokkaido patients
had normal chest radiography findings (p < 0.001). Reversion to normal
chest-radiography findings with time is recorded in Table XI and Fig. 10.
Fig. 10: Percentages of normalized chest radiographs in patients with
initial stage-II disease in Finnish and Hokkaido hospital patients,
including Finnish patients with EN during five years of follow-up.
Patients with initial stage-III changes
Fifty-eight Finnish and 23 Japanese patients had initial stage-III lesions.
Findings in 24% of Finnish patients and 35% of Japanese patients became
normal during five years of follow-up. The difference is not statistically
significant. Developments with time are shown in Table XI.
Patients with initial stage-I radiographic findings and erythema nodosum
Sixty-three of the Finnish patients had initial stage-I chest-radiography
changes and exhibited EN on diagnosis or had a history of EN a few weeks
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prior to diagnosis of sarcoidosis. In 51% chest radiography findings became
normal during a follow-up period of two years, in 59% after a 5-year follow-
up period. The difference in outcome between Finnish sarcoidosis patients
with and without EN is significant (p < 0.001). Both regarding normalization
of chest radiographs in patients with initial stage-I changes and EN are
recorded in Table XI and Fig. 9. No EN patient developed parenchymal
lesions during follow-up.
No Hokkaido sarcoidosis patient presented with EN. EN occurred during
follow-up in three patients. Comparison of outcomes between Finnish and
Hokkaido patients with EN was not possible because of the small number of
Hokkaido EN cases.
Patients with initial stage-II radiographic findings and erythema nodosum
Thirty-eight Finnish patients had EN and stage-II chest radiographic
findings. After one, 2, 3, 4 and 5 years, 18%, 34%, 45%, 47% and 53% of
patients, respectively, had normal chest radiography findings. Outcomes in
stage-I and stage-II patients with EN are not statistically significantly
different. Both regarding normalization of chest radiographs in patients with
initial stage-II changes and EN are recorded in Table XI and Fig. 10.
Influence of age on prognosis
The two series of patients were first divided into subgroups of these below
and above 30 years of age. In the Finnish series, there were 91 patients in
the younger age group, 346 patients in the older. Pulmonary radiographic
changes did not develop significantly differently between the two age
groups. In Hokkaido there were 323 patients in the younger are group,
123 in the older. Significantly lower percentages of Hokkaido patients more
than 30 years of age than younger patients had normal chest radiographs
(p < 0.001 at all times during follow-up).
The younger Hokkaido patients exhibited a significantly higher rate of
normalization of chest radiographs during the five years of follow-up than
Finnish patients (p < 0.001) (Table XI). The same was true for all Hokkaido
and Finnish patients and for Hokkaido and Finnish patients with initial
stage-I findings. For Hokkaido and Finnish patients with initial stage-II
findings the differences between the two groups are not significant after
one and two years of follow-up, but differences are statistically significant
(p < 0.001 after three, four and five years of follow-up). Numbers of patients
with initial stage-III findings were too few to allow meaningful comaprisons.
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Influence of sex on outcome
Forty-two per cent of Finnish female patients and 71% of Hokkaido female
patients, and 36% of Finnish male patients and 75% of Hokkaido male
patients developed normal chest radiographs during five years of follow-up.
There were no statistically significant differences between the sexes in
Finland and Hokkaido. However, the differences between Finnish and
Japanese patients are statistically significant for both female and male
patients (p < 0.001). Developments in chest-radiography findings according
to sex are recorded in Table XI and Fig. 11.
Fig. 11: Percentages of normalized chest radiographs according to sex in
Finnish and Hokkaido hospital patients during five years of follow-up.
Influence of presenting symptoms on outcome
Two hundered and fifteen Finnish patients and 261 Hokkaidoan patients
with pulmonary sarcoidosis presented without symptoms. During the first
year of follow-up, 12% of the Finnish patients and 52% of Hokkaido
patients developed normal chest radiographs. After five years of follow-up,
28% and 77%, respectively, had developed normal chest radiographs.
Differences in percentages of patients with normal chest radiography
findings between the two series were significant at all times (p < 0.001).
The influence of symptoms on outcome is summarized in Table XI and
Fig. 12.
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Influence of extrapulmonary findings on outcome
Extrapulmonary lesions were initially diagnosed in 298 Finnish patients
(68%) and 244 Hokkaido patients (53%). Excluding the 101 Finnish
patients with EN who have been discussed separately there were 197
Finnish patients with extrapulmonary lesions. After five years of follow-up,
34% of these Finnish patients and 68% of the Hokkaido patients with initial
extra-pulmonary lesions had developed normal chest radiographs. The
difference is significant (p < 0.001). Follow-up data are recorded in
Table XI.
In Finland, 42% of patients without extrapulmonary lesions developed
normal chest radiographs. This percentage is higher than the 34% for
patients with extrapulmonary findings. The difference is not statistically
significant (p < 0.1). The corresponding percentages for Hokkaido were
76 (patients without extrapulmonary lesions) and 68 (patients with
extrapulmonary lesions). This difference is significant (p < 0.05). Normali-
zation in Hokkaido patients without eye sarcoidosis was also statistically
significantly better than that in patients with eye sarcoidosis. After one
year of follow-up 41% of patients with ocular lesions had normal chest
radiographs compared with 51% of patients without (p = 0.05). After five
years the corresponding percentages were 67 and 79, respectivly (p = 0.01).
Fig. 12: Percentages of normalized chest radiographs in patients without
symptoms on diagnosis in Finnish and Hokkaido hospital patients during
five years of follow-up.
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Influence of treatment on outcome
As previously mentioned disease severity differed between untreated and
treated groups of patients. In Finland 136 patients (31%) received treatment,
in Hokkaido 106 patients (23%). Indications for commencement of
treatment with corticosteroids, and treatment regimens, were similar in
Finland and Hokkaido. In most cases, extrapulmonary manifestations
alone or with pulmonary findings were the reason for starting treatment.
Pulmonary sarcoidosis without extrapulmonary manifestations was treated
only if there was radiographic evidence of progression of infiltrates during
follow-up, or there was obvious impairment on the basis of diffusion
capacities and spirometric volumes. In Finland 87 patients (47% of stage-II
or stage-III patients) in Hokkaido 51 patients (41%) received treatment on
this basis. Patients exhibiting stage-I radiographic changes alone, without
extrapulmonary manifestations, were not usually treated. Comapisons of
pulmonary radiographic findings for treated and untreated Finnish and
Hokkaido patients revealed statistically significantly better development in
the latter (p < 0.001).
Completely normal chest radiographs were significantly commoner in
all untreated patients than in treated patients (p values between < 0.01 and
< 0.001 one to five years of follow-up). These findings are, however, of
limited interest, as treatment always had been given in non-random fashion
and to patients with more severe disease. Chest radiographic findings that
were not completely normal were neverthless better in steroid-treated patients
with stage-II to stage-III pulmonary findings as the sole indication for
starting treatment (p values between < 0.01 and < 0.001 after one to five
years of follow up) than in untreated patients.
5.4. Familial sarcoidosis
in Finland and Hokkaido (Study IV)
Prevalence of familial sarcoidosis and family relationships
In the 1984 surveys, 1378 Finnish patients with a diagnosis of sarcoidosis
and 208 Hokkaidoan patients were seen in hospital. Fifty Finnish and 9
Hokkaido patients had family members who had also had sarcoidosis. In the
two Mjölbolsta and Sapporo Hospitals, 571 Finnish and 686 Hokkaido
patients were diagnosed as having sarcoidosis. Twenty-seven the Finnish
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Table XII:
Frequencies of occurence of different family relationships in Finnish
(Mjölbolsta) and Hokkaido (Sapporo) hospital series.
Mjölbolsta (27 families) Sapporo (20 families)
Type of relationship Number of cases; (per cent) Number of cases; (per cent)
Sibling: 26 (46) 18 (45)
Sister-sister 6 4
Brother-brother 2 4
Brother-sister 18 10
Parent-child: 26 (46) 12 (30)
Mother-child 16 12
Mother-child-sister 3 0
Father-child 4 0
Father-child-grandchild 3 0
Cousins 0 (0) 4 (10)
Others 4 (7) 6 (15)
Nieces 2 4
Nephews 2 2
Total 56 40
patients and 20 of the Hokkaido patients had family members who had had
sarcoidosis. These results give prevalences of familial sarcoidosis in Finland
of 3.6 to 4.7%, in Hokkaido of 4.3 to 2.9%.
There were 13 sibling pairs and 12 parent-child pairs in the Finnish
hospital series. The corresponding figures for Hokkaido were nine and
six, respectively. There were no cousins in the Finnish series but two in the
Japanese series. There were two nieces or nephews in the Finnish series,
three in the Japanese series. Family relationships are shown in Table XII.
Clinical picture and outcome
The familial cases in the two hospital series were compared with the rest of
the sarcoidosis cases. Statistics and clinical pictures relating to Finnish and
Japanese familial sarcoidosis cases are recorded in Table XIII. Six of the
Finnish familial patients (22%) and 96 of the non-familial Finnish sarcoidosis
patients (18%) had EN. In Hokkaido, only three EN cases occurred, all
among non-familial sarcoidosis patients. Eye involvement was commoner
in Hokkaido sarcoidosis patients: There were eight familial (20%), 336
non-familial cases (51%) (p < 0.001). The corresponding Finnish figures
for eye envolvement were one and 26.
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Table XIII:
Statistics relating to and clinical picture in patients with familial
sarcoidosis in hospital series of 571 Finnish patients (Mjölbolsta) and 686
Hokkaido patients (Sapporo).
                     Mjölbolsta                         Sapporo
Familial Non-familial Familial Non-familial
No. of families 27 20
No. of cases 56 544 40 646
Female/ male ratio 0.9 1.5 1.4 1.2
Age (years) 39.5 41.6 35.9 30.0
Chest X-ray:
Stage I 14 256 38 315
Sttage II 9 216 1 136
Stage III 4 64 1 33
Extrathoracic findings
Erythema nodosum 6 96 0 3
Eye findings 1 26 8 336
Familial cases in the two countries had slightly less favourable outcome
(normalization of chest radiographs) during five years of follow-up than
non-familial cases. No statistically significant differences were found
between familial and non-familial series in either Finland or Japan but
familial and non-familial sarcoidosis patients in Hokkaido had statistically
significantly better outcome than patients in Finland.
5.5. Association between sarcoidosis and
HLA-B7, -Cw7 and -DR2 in a Finnish
sarcoidosis population (Study V)
HLA pattern in sarcoidosis patients
The study involved 20 consecutive patients with a diagnosis of sarcoidosis
in the Mjölbolsta Hospital. The control population consisted of 10,000
Finnish-bone marrow donors. Statistically significant excesses in
frequencies of HLA-B7 (p = 0.002), -Cw7 (p = 0.0002, p
c
 < 0.01) and
DR2 (p = 0.0003, p
c
 = 0.012) were found in sarcoidosis patients. HLA-B7,
-Cw7 and -DR2 coincided in 10 patients.
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Frequencies of HLA-A2, -B8, -B22 and -DR3 were higher but not
statistically significantly in sarcoidosis patients than in controls. HLA-B27
and -Cw4 were less common in sarcoidosis patients than in controls but
not statistically significantly.
The odds ratio (OR) relating to the excess of HLA-Cw7 was 5.1 (95%
confidence interval 2.3 - 11.5), that for the deficit of HLA-B27 0.3
(95% confidence interval 0.2 - 0.5).
To confirm the findings Cw* typing for 18 DNA samples was also
performed. Cw*07 was found in 13 sarcoidosis patients (72%), two of
whom were serologically Cw7 negative. One clearly Cw7 seropositive
sarcoidosis patient was Cw*07 negative. In 88 control subjects who had
been routinely HLA-typed serological and DNA typing revealed Cw7Cw*07
in 41 cases, and Cw*07 alone in two cases. Two uncertain Cw7 findings
were Cw*07 negative.
HLA antigens and clinical picture (unpublished data)
Statistically significant associations were found between EN and HLA-B8
in four of six cases (p = 0.037) and -DR3 in four of six cases (p = 0.0279).
The other common symptom, dyspnoea, was not found to be HLA-associated.
HLA antigens, chest radiography
findings and outcome (unpublished data).
Ten of the 20 sarcoidosis patients had normal chest radiography findings
after follow up for one to two years. Eight of them had HLA-B7, an excess
(p = 0.069) as compared with the other 10 patients (three B7 positives). In
three other patients radiography findings were normal within one further
follow-up year. None was HLA-B7 positive. After four years of follow-up
the radiographic findings were normal in 13 patients. In the remaining
patients the active disease persisted for longer. Both chest-radiographiy
changes (stage-I to stage-III) and high levels of biochemical markers of
sarcoidosis activity remeined. No statistically significant associations were
found between less favourable outcomes of sarcoidosis and persistance of
chest-radiographic findings and HLA types. No associations were found
between the most prevalent HLA types, Cw7 and DR2, and chest-radiography
findings and outcome of sarcoidosis.
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5.6. Association of angiotensin-converting
enzyme DD gene with poor outcome
in Finnish sarcoidosis patients (Study VI)
ACE genotype frequencies are shown in Table XIV. Frequencies of the D
allele were higher in controls and sarcoidosis patients than frequencies of
the I allele (0.51/0.49 and 0.58/0.42 respectively), but the differences were
not statistically significant.
Table XIV:
ACE genotype and allele frequencies in Finnish sarcoidosis patients and
controls.
Female Male Total
Patients Controls Patients Controls Patients Controls
N = 42 N = 47 N = 16 N = 23 N = 59 N = 70
Genotype
frequency
DD (%) 12 (29) 14 (30) 6 (38) 5 (22) 18 (31) 19 (27)
ID (%) 23 (55) 23 (49) 9 (56) 11 (48) 32 (54) 34 (49)
II (%) 7 (17) 10 (21) 2 (13) 7 (30) 9 (15) 17 (24)
Odds ratio* 1.17 3.08 1.45
95% CI 0.41-3.32 0.50-18.9 0.60-3.49
P values 0.77 0.22 0.41
Allele frequency
D 0.56 0.54 0.625 0.46 0.58 0.51
I 0.44 0.46 0.375 0.54 0.42 0.49
P values  0.82    0.14 0.32
* :Ratio of DD + ID to II. CI: Confidence interval
Outcomes in sarcoidosis patients according to ACE genotype are shown in
Table XV. Only two of 18 patients with the DD genotype had favourable
outcomes. In three the outcome was classed as intermediate. Patients with
good outcomes were compared with patients in whom outcomes were poor
or intermediate. A good outcome was statistically significantly less common
in patients with the DD genotype than in patients with the II and ID
genotypes (p < 0.05). Thirteen of the 18 DD patients had poor outcomes.
This ratio is statistically significantly different from corresponding ratios
relating to patients with II or ID genotypes (p < 0.01).
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Erythema nodosum: Eleven patients (4 DD, 4 ID and 3 II) had had EN,
a sign that outcome is likely to be good. The three patients with the II
genotype and three of the four patients with the ID genotype had good
outcomes. Three of the four EN patients with the DD genotype had poor
outcomes. The difference between the DD patients and the II and ID patients
are statistically significant (p < 0.05).
Table XV:
Outcomes in Finnish sarcoidosis patients by ACE genotypes.
   Genotype
Outcome II ID DD
Good 4 12 2
Intermediate 4 8 3
Poor 1 12 13
Total 9 32 18
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6. DISCUSSION
Study populations and methods
The system used to calculate incidences and prevalences of sarcoidosis in
Finland and Hokkaido were different. For many Japanese, annual chest
radiographic examinations had been compulsory. The first nationwide
epidemiological sarcoidosis survey was performed in Japan in 1960. Others
have followed. Sarcoidosis has been found more often in Hokkaido than
other parts of Japan. Hosoda et al. (25) found the incidence of sarcoidosis
in Hokkaido to be 4.8 per 100,000. In Kyushu, the main southerly island
of Japan, it was only 0.5 per 100,000. This regional difference in Japan
has persisted. A national survey in 1984 resulted in prevalence figure
(non-adjusted for age) of 1.5 per 100,000 for Japan as a whole but 5.0 per
100,000 for Hokkaido. Annual incidence was 0.3 per 100,000 in Japan as
a whole but 0.7 per 100,000 in Hokkaido (12). In Hokkaido, only hospitals
with 200 beds or more were asked to report numbes of sarcoidosis patients
visiting them in1984. True incidences and prevalences therefore had to be
estimated (103, 104).
In Finland, mass radiographic surveys have been performed only every
third year. Possibilities of finding sarcoidosis cases have therefore been
more limited in Finland than in Japan. However, according to reports at
international conferences on sarcoidosis the incidence and prevalence of
sarcoidosis in Finland has always been much higher than in Japan (Tables
II-III). Finnish prevalences for sarcoidosis as high as 102 per 100,000 have
been reported (9). The true difference may therefore have been under-
estimated.
Although Japanese incidence and prevalence figures are partly estimated
and the Finnish system for finding the cases has been different from that in
Japan, the results of this comparative study confirm that there are substantial
differences in incidences and prevalences of sarcoidosis between Hokkaido
and Finland. The differences are real, since differences in diagnostic
procedures and classifications can be excluded, even though raw data could
not be checked for all patients in Hokkaido.
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Validity of diagnosis
To study the clinical picture and course of sarcoidosis, and the occurrence of
familial sarcoidosis in Finland and Hokkaido, two large hospital series
(Mjölbolsta 571 patients, Sapporo 686 patients) were evaluated in similar
ways by members of our study group. Identical diagnostic criteria were
used. These are described on pp. 30 to 31. They are based on papers by
Hiraga and Hosoda (108, 109). The clinical pictures presented by patients
differed greatly in the two countries. Ocular sarcoidosis was prevalent in
Japan. In 1984, 44% of Japanese male patients and 59% of female patients
had eye lesions (12). Findings in present Sapporo series were similar. If
a patient meets at least two of the three criteria compatible with sarcoidosis
(histological verification, chest-radiography findings, typical clinical
picture) a diagnosis of sarcoidosis is obviously reasonable. However,
reliability of diagnosis in Sapporo Hospital patients on the basis of typical
clinical picture alone (visual disturbances and/or findings) has been
questioned (110). In such a situation, increases in S-ACE and/or S-LZM
have been shown to be of diagnostic value (111, 112). These biochemical
markers were used as supportive tools in our Japanese work. In previous
studies, patients with ocular sarcoidosis have usually had abnormal chest-
radiography findings. However, when ocular lesions are present, chest-
radiography changes may not be evident, or may have resolved (37, 113).
In our study, a number of patients with only ocular symptoms/changes on
presentation subsequently developed chest-radiographic lesions later,
according to oral information provided by a member of the Japanese study
team. Hilar/mediastinal lymphadenopathy was also verified by CT scanning
of patients with normal chest radiography findings. On the basis of follow-
up information and high values for serum markers of activity the diagnoses
of sarcoidosis in Sapporo patients exhibiting only typical clinical pictures
are therefore considered reliable.
Age and sex distribution
The results of the 1984 series indicated that the sex distribution of sarcoidosis
did not differ significantly between Finland and Hokkaido. Findings in
the two hospital series and in previous studies in Finland and Japan have
been similar (1, 6, 8).
One noteworthy feature is that sarcoidosis patients in Finland were
significantly older at the time of diagnosis than patients in Hokkaido. In
previous Japanese studies (12, 25, 28) the age group 20-29 years has been
largest. In the largest Finnish study (8), the age group 30-39 years was
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largest. In Swedish and Danish series (18), and in most sarcoidosis studies
elsewhere (1), younger age groups have been largest. The age distribution
in Finland, with predominance of patients more than 30 years of age, is
therefore exceptional. The reason is unknown. The more effective and
frequent screening system in Japan may result earlier detection of the disease.
Environmental factors, and dietary and smoking habits
It has been suggested that mycobacterial infection can lead to sarcoidosis
(114, 116). Incidences and prevalences of tuberculosis in Finland and
Hokkaido at the time of our study, and earlier have been similar. Differences
in exposure to mycobacteria therefore probably do not explain the
differences in incidences and prevalences of sarcoidosis between the two
countries.
It has also been suggested that climate features (7f) and exposure to
pine pollen (116) can lead to sarcoidosis. The climates in Finland and
Hokkaido are similar (13). No correlation between distribution of pine
forests and cases of sarcoidosis has been found in Finland (22) or Japan
(117). It is therefore unlikely that such enviromental factors could explain
differences in incidences and prevalences of sarcoidosis.
Dietary habits in Japan differ from those in Finland. The Japanese eat
more fish and vegetables, Finns eat mainly meat, and fewer green
vegetables. In a Japanese case-control study a low intake of green vegetables
has been shown to be associated with sarcoidosis (118). Since our study
was retrospective we were unable to evaluate whether dietary habits had
any effect.
Smoking habits differ between Finland and Hokkaido. The Japanese
smoke more than Finns. Published data suggest that smoking can reduce
the risk of suffering from sarcoidosis (119, 120) but there is also a report
claiming no protective effect (121). Full information about the smoking
habits of the sarcoidosis patients in the 1984 surveys in Finland and
Hokkaido is lacking. However, they could partly explain the differences in
incidences and prevalences of sarcoidosis.
Differences in clinical pictures and chest-radiographic findings
It has has been shown that race affects the incidence and prevalence, clinical
picture and course of sarcoidosis (1, 32, 49). The clinical picture of
sarcoidosis has been shown to differ in Finland and Japan (1, 6, 14). This
was also found in our study, although a number of similarities were found
between patients in the hospital series in these two countries.
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Forty-four per cent and 50% of patients were symptom-free at time of
diagnosis in the Finnish and Hokkaido series, respectively. In the largest
Finnish study previously reported, 39% of patients were diagnosed following
by routine chest-radiographic examinations (8). In previous Japanese
studies, mean percentage of symptom-free patients was similar (around
50%) but percentages ranged from 15 to 80 depending on age and sex
(28). Because of the differences in performance of mass-radiographic
surveys in the two countries (annual mass-radiographic surveys in Japan
every year, in Finland every third year), the percentage of symptom-free
patients in Finland could in reality have been still higher.
The most important difference between the Finnish and Hokkaido
hospital series relates to symptoms on presentation. Finnish patients often
had cough with fever, arthralgia and EN. The latter was never seen as
a presenting symptom in the Hokkaido series but appeared during a follow-
up period of five years in three cases. Many Hokkaido patients had
eye symptoms, but these were rare in Finnish patients. The reasons for
the differences are unknown but genetics may have some influence,
as discussed below. Unknown antigen differences, may be another
explanation.
No statistically significant difference in percentages of patients
exhibiting tuberculin-skin-test positivity was found between the two hospital
series. This was to be expected, since percentages of tuberculin-skin-test-
negative subjects are similar, 10%, in the general populations in the areas
concerned (29, 122). BCG vaccination systems have also been similar. In
Japan all newborn infants are BCG-vaccinated at age 3 months. In Finland,
vaccination takes place during the stay in the maternity hospital.
Results of lung-function tests (FVC, FEV1, DLco), expressed as
percentages of predicted values, were within normal ranges in both hospital
series. The lower percentage relating to FEV1 in Sapporo indicates that the
patients there were probably, more obstructed. The explanation may lie in
the fact that smokers were commoner in the Sapporo patients than in the
Finnish patients.
Chest-radiographic findings at time of diagnosis were commoner and
more serious in the Finnish series than in the Hokkaido series. Only 1% of
Finnish patients had normal chest-radiographic pictures as compared with
19% of Japanese patients. Fifty-one per cent of Finnish patients but only
17% of Hokkaido patients had stage-II or stage-III findings in their chest
radiographs. Frequencies and types of changes in chest radiography findings
in previous studies were similar (8, 18). In a Japanese study (12), the
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percentage of sarcoidosis patients exhibiting no chest-radiography changes
was lower than in our study.
Differences in outcome in pulmonary sarcoidosis
Although it would appear possible to diagnose sarcoidosis clinically without
biopsy in Finnish patients with EN and stage-I to stage-II pulmonary
findings, and in Japanese patients with ocular manifestations and stage-I
to stage-II disease, in our study we included only patients with positive
tissue-biopsy findings supporting clinical diagnosis of sarcoidosis. After
careful re-evaluation of all hospital data very few re-classifications were
undertaken. Normalization of chest radiographs occurred significantly
oftener and more rapidly in Japanese stage-I and stage-II sarcoidosis patients
than in Finnish patients. Finnish findings resemble findings in Scandinavian
studies (40, 123). In Japanese sarcoidosis studies rates for clearance of
chest radiographs have been found to be similar to those in Japan in our
study (11, 57, 59). Clearance of chest-radiography findings was overall
significantly better in Japanese patients than in Finnish pateints. EN in
patients with sarcoidosis has been widely associated with a good outcome
(8, 40, 54, 123). EN is more prevalent in Scandinavian and other European
sarcoidosis patients than in patients elsewere (1, 18, 124). An association
has been shown between EN and the histocompatibility antigen HLA-B8
(85). HLA-B8 is extremely rare in the Japanese population. This could explain
the rarity of EN in our Japanese series. The Japanese patients have a
different HLA background (95). Patients with good outcomes often have
a genotype including HLA-DRw5 (94). In the our study, there was no EN
on diagnosis in the Japanese patients, but 18 to 23% of Finnish patients
had EN. Neverthless, overall, outcome in Japanese stage-I patients were
better than outcomes in Finnish patients with EN. These facts suggest that
EN alone is not indicative of a favourable outcome in sarcoidosis. There are
reports of poor outcomes in sarcoidosis patients with EN (54, 83).
In previous studies, age has been discussed as a prognostic factor. It has
been shown that patients below 30 years of age (57, 59) or 40 years of age
(8, 54, 123, 125) had a better outcomes than older patients. In our study, age
was a factor in relation to Japanese patients. In the younger age group, 80%
exhibited normalization of chest-radiography findings. In the Finnish
series the difference in outcomes between younger and older patients was
not statistically significant.
The influence of sex on the incidence and prevalence, and outcome in
sarcoidosis has been discussed in a number of papers (8, 54, 57, 59, 123).
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No marked differences have been found. In our study, sex did not
significantly affect outcome. There were no significant differences
between the sexes in the Finnish or Japanese series. The widely cited view
that female sex is associated with a good prognosis (45) was not supported
by the results of our study.
Results of previous studies indicate that sarcoidosis patients with
extrathoracic lesions (excluding EN) have more severe disease and poorer
outcomes (3, 8, 40, 94, 1232) than patients without extrapulmonary
manifestations. In a study in Finland, this was found to be true in relation
to patients symptom-free on diagnosis but not patients with initial
symptoms, including EN (125). In a Japanese study, a correlation was
observed between less favourable outcomes and the presence of
extrapulmonary disease manifestations (57). In our study after five years
of follow-up of the two hospital series, Japanese patients were found to
have experienced better outcomes overall than Finnish patients. The
presence or absence of extrapulmonary lesions did not significantly
influence the development of chest-radiography findings in Finnish patients.
Japanese series patients without extrapulmonary lesions experienced
normalization of chest radiographs significantly more often than patients
with extrapulmonary manifestations. Our two series of patients included
sufficient numbers of three types of extrapulmonary manifestation to allow
their influences on development of pulmonary findings to be assassed.
The extrapulmonary manifestations were peripheral lymphadenopathy in
both countries, EN in Finland and ocular sarcoidosis in Japan. Other
extrapulmonary lesions were too infrequent to allow their influence on
outcome in pulmonary sarcoidosis to be assessed. Patients with peripheral
lymphadenopathy experienced pulmonary radiography development
similar to those in patients without enlarged lymph nodes, in both countries.
Finnish patients with EN had better outcomes than patients without EN, in
agreement with previous observations (8, 54). The percentage of Japanese
patients with ocular sarcoidosis experiencing normalization of chest-
radiography findings was significantly lower than in patients with no ocular or
other extrapulmonary lesions, also in agreement with previous findings (11).
Treatment with corticosteroids did not account for the difference in
outcome between Finnish and Japanese patients. Normalization of chest
radiography findings was significantly commoner in untreated patients in
Finland and Japan. However, severity of sarcoidosis differed greatly
between untreated and treated groups of patients. There was no random
allocation to treatment with corticosteroids or lack of it in Finnish or Japanese
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patients. Comparison of outcomes in pulmonary sarcoidosis between patients
treated and not treated with corticosteroids is therefore meaningless.
In patients with parenchymal lesions as an indication for treatment with
corticosteroids improvement was fastest in treated patients.
Influences of ethnic and genetic factors on incidence and prevalence,
clinical picture and outcome in sarcoidosis
It has been suggested that genetics may be important in sarcoidosis. In
different ethnic groups incidences and prevalences of sarcoidosis are very
different (1). About 500 cases of sarcoidosis with familial connections have
been published. The prevalence of familial sarcoidosis has shown to be
higher than prevalence of sarcoidosis in the background population (61,
62). The histocompatibility system has been shown to be related to the
clinical picture and outcome in sarcoidosis but seldom to susceptibility to
sarcoidosis (83, 126, 127, 128). There have been thoughts that a recessive
autosomal (65) or heterogenic heredity (64) may be a background factor
in sarcoidosis.
The populations of Finland and Hokkaido are different ethnically. They
may therefore have different genetic susceptibilities to sarcoidosis. There
are also studies showing differences in incidences and prevalences of
sarcoidosis, and in prevalence of familial sarcoidosis between different ethnic
groups (31, 67). Some human leukocyte antigens have been found
more often than expected in patients with sarcoidosis (7g, 73, 74, 75).
Other studies have shown that some HLA types protect against sarcoidosis
(79). In Japan the commonest HLA types in the sarcoidosis population are
HLA-A1, -Bw46, -Cx46, -DRw8, -DRw9 and -DRw52, HLA-DRw52 being
the most prevalent (94, 95). There have been no previous HLA studies in
sarcoidosis patients in Finland but a case report on a family has shown an
association between HLA-B8/DR3 and patients with sarcoidosis or Crohn’s
disease (91). However, individuals with Löfgren’s Syndrome (sarcoidosis
with EN and BHL, which is common in Finland and Scandinavia), most
often have the HLA-B8 (3, 40, 54). In Japan HLA-B8 is almost nonexistent.
In our study on HLA and sarcoidosis, an association between susceptibility
to sarcoidosis and HLA-Cw7 and -DR2 was found. It cannot therefore be
excluded that genetic differences influence incidence and prevalence of
sarcoidosis although the mechanism of heredity is not yet clear. On the
other hand heredity is probably not the only factor leading to sarcoidosis.
It has been found in previous studies that the clinical picture of
sarcoidosis varies widely between ethnic groups (1, 14). In our study,
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patients in the two hospital series were of different race. Their heredity and
HLA backgrounds therefore differed. In our study on HLA and sarcoidosis
in Finland frequencies of B8 and DR3 were twice as high and almost twice
as high, respectively, in the sarcoidosis population than in the controls, but
there was no statistically significant association with susceptibility to
sarcoidosis, nor was there an association between HLA-B8 and DR3 and
good outcome. In Sweden, a study has shown a high prevalence of HLA-B8
(67%) and -DR3 (90%) in sarcoidosis patients, with an association between
EN and favourable outcome (83). Another recent Swedish study has shown
an association between good outcome and HLA-DR17(3) (87). In two
Japanese studies DRw52 has been found to be the most prevalent HLA
type, and to be associated with a favourable outcome. In Japan, HLA-B8
and -DR3 are extremely rare (94, 95). EN and arthralgy, usually associated
with these HLA types, are also rare in Japan.
On the basis of histopathological and chest radiography findings,
sarcoidosis must be considered to be the same disease in Finland and
Hokkaido. However, symptoms on diagnosis, mode of presentation and
clinical picture vary considerably between Finland and Hokkaido. The
reasons for the differences are unknown but difference in heredity may
be important.
It has been shown that both HLA-B8 and -DR3 are associated with
good outcome. Berlin et al. have shown in 122 sarcoidosis patients that
those with HLA-DR17(3) had significantly better outcomes within 2 years
than those with HLA-DR14(6) or -DR15(2) (87). There are also other
studies relating to HLA types that indicate of a poor outcome in sarcoidosis
e.g. in Italy HLA-DR5 (89). Japanese studies have, however, shown that
HLA-DR5 may be associated with good outcome (94, 95). In our study on
HLA and sarcoidosis, the association between HLA-B7 and good outcome
(unpublished data) was almost statistically significant.
In our follow-up study of patients in the two hospital series, EN as a
presenting symptom was not seen in Hokkaido but was seen in 18% of
Finnish patients. The outcomes in Hokkaido stage-I patients were
nevertheless better overall than outcomes in Finnish patients with EN. This
suggest that occurrence of EN does not mean the outcome will always be
favourable as already stated on page 64. There are also reports of poor
outcomes in sarcoidosis patients with EN (54, 83).
The results of our study on ACE gene polymorphism may partly explain
the poorer outcomes in Finnish sarcoidosis patients than in Japanese
patients. Patients with the DD genotype had poorer outcomes than the
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others. In our study and in previous studies (98-102), Caucasians had the D
allele more often than Japanese subjects. In Japanese studies the DD
genotype was found to be present in lower percentages of sarcoidosis patients
(38% and 39%) (99 101) than in our study (58%).
Despite the differences in incidences and prevalences, clinical pictures
and outcomes of sarcoidosis in Finland and Hokkaido, prevalences of
familial sarcoidosis were similar in both areas. According to results of
Japanese studies (94, 95) and our study on HLA and sarcoidosis in Finland,
HLA patterns and ACE genotypes differ between Finnish and Hokkaido
sarcoidosis patients  (99, 101). The most important reasons for differences
between sarcoidosis in Finland and Hokkaido appear to be the racial and
genetic. The inheritance pattern of sarcoidosis appears complex but
remains unresolved.
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7. SUMMARY AND CONCLUSIONS
Finland and Hokkaido resemble each other in a number of respects. The
four-season climates, with cold winters and cool summers are similar.
Incidences and prevalences of tuberculosis are also similar. The two areas
have populations of similar sizes. The populations are, however, of different
race. The Japanese eat fish oftener than the Finns. Prevalence of smokers
is higher in Japan than in Finland. Studies in Finland and Japan have
shown differences in incidences and prevalences and clinical pictures of
sarcoidosis.
To asses whether reported differences relating to sarcoidosis between
Finland and Hokkaido are real, or could be explained by differences relating
to classification, terminology or diagnostic procedures, comparative
studies were performed. Information  was collected identically for both
areas, and cases were evaluated by a joint team.
Results relating to two series of sarcoidosis patients in both areas were
studied: 1) sarcoidosis patients from the 1984 surveys in Finland (n = 1378)
and Hokkaido (n = 208), to determine incidences and prevalences of
sarcoidosis and 2) patients from Mjölbolsta Hospital in Finland (n = 571)
and Sapporo Hospital ( n = 686) to asses clinical pictures of sarcoidosis in
the areas concerned.
Outcomes were determined from 5-year follow-up data relating to patients
with biopsy-proven pulmonary sarcoidosis (437 Mjölbolsta Hospital cases,
457 Sapporo Hospital cases).
In all series familial sarcoidosis cases were also evaluated. To try to
improve understanding of the heredity of sarcoidosis, 20 Finnish sarcoidosis
patients, and their HLA phenotypes were stdied.
ACE genotypes in 59 Finnish sarcoidosis patients and 70 controls were
determined. Outcomes in sarcoidosis in patients with the II, ID or DD
genotypes were established.
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1. The incidence and prevalence of sarcoidosis were higher in Finland
than in Hokkaido: crude annual incidences were 11.4 and 2.8 per 100,000
inhabitants and crude prevalences 28.2 and 7.2 per 100,000 inhabitants,
respectively. The Hokkaido sarcoidosis patients were younger than
the Finnish patients. Mean ages were 40 and 45 years, respectively.
2. Half of the patients in Finnish and Hokkaido hospital series were first
diagnosed via mass-radiographic surveys. In patients diagnosed on
the basis of symptoms these varied considerably. In Finnish patients
cough, fever, general malaise, dyspnoea and EN were prevalent. In
Hokkaido patients eye distubances were commonest. Fewer than a
half of the Finnish patients but more than half of the Hokkaido patients
exhibited bilateral hilar lymphadenopathy as an initial radiographic
finding (stage-I). Stage-II and stage-III changes were more often seen
in Finnish patients than in Hokkaido patients. Normal chest radiographs
were very seldom seen in Finnish patients but occurred in almost 20%
of Hokkaido patients.
3. Normalization of chest-radiography changes in patients with biopsy-
proven sarcoidosis occurred in 40% of Finnish patients and 73% of
Japanese patients. Of the 191 Finnish and 309 Japanese patients
with stage-I sarcoidosis, 47% and 76%, respectively, experienced
normalization of chest-radiography findings during five years of follow-
up. The Finnish series included patients with EN, of whom 59%
experienced normalization. Of 186 Finnish and 125 Japanese patients
with initial stage-II disease, 36% and 73%, respectively, experienced
normalization of chest-radiography findings during follow-up. There
was no significant difference in percentages of the 58 Finnish 23 and
Japanese patients with initial stage-III chest radiography changes
who experienced normalization. Sex did not influence outcome in
sarcoidosis. Age had no influence in the Finnish series but Japanese
patients below 30 years of age had significantly better outcomes than
older patients. There were extrapulmonary findings in 298 Finnish and
244 Japanese patients. After follow-up for five years, 34% of Finnish
patients (excluding the 101 patients with EN) and 68% of Japanese
patients had normal chest radiographs.
4. Prevalences of familial sarcoidosis on the basis of the 1984 surveys
and the hospital series were 3.6 to 4.7% in Finland, 4.3 to 2.9% in
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Hokkaido. In both series sibling-sibling and mother-child relationships
predominated.
5. Statistically significant associations between frequencies of HLA-Cw7,
-DR2 and -B7 and sarcoidosis patients were seen in Finnish patients
compared with healthy Finnish controls. In Japanese studies, HLA-
DRw52 has shown to be commonest in Japanese with sarcoidosis but
B8 is very rare. Patients with HLA-DRw52 and -DR5 have been shown
to have better outcomes.
6. In Finns, ACE genotypes (II, ID, DD) did not statistically significantly
differ in frequency of occurrence between patients and controls.
Statistically significantly more patients with the DD genotype had poor
outcomes than patients with the II and ID genotypes. Patients with
Löfgrens Syndrome (stage-I chest-radiography changes and EN) and
the DD genotype also had poor outcomes. In Japanese studies the I
allele has shown to be dominant in the population. An association between
less favourable outcome in sarcoidosis and the ACE DD genotype has
also been demonstrated.
Differences in incidences and prevalences, clinical pictures and
outcomes in sarcoidosis between Finland and Hokkaido were marked.
Differences in racial background obviously at least partly explain the
findings. Certain HLA gene combinations (haplotypes) may in particular
serve as markers for gene(s) affecting the clinical expression of sarcoidosis
and how it originates. This could explain the differences in clinical pictures
and outcomes between Finnish and Hokkaido sarcoidosis patients. The
ACE genotype may also be a prognostic marker in sarcoidosis. The low
frequency of occurrence of ACE gene allele D in Japan could partly explain
why outcomes in Japanese with sarcoidosis are better than in Finns with
sarcoidosis.
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